

CITATION REPORT

List of articles citing

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

DOI: 10.1056/nejm199008303230904

New England Journal of Medicine, 1990, 323, 570-8.

Source: <https://exaly.com/paper-pdf/21758533/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1139	Gene expression using retroviral vectors. 1990 , 1, 55-61		4
1138	Gene therapy. 1990 , 1, 196-208		
1137	Gene transfer into humans: a first step. <i>New England Journal of Medicine</i> , 1990 , 323, 601-3	59.2	8
1136	Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study. 1990 , 1, 373-84		26
1135	Whither goest thou, gene therapy?. 1990 , 1, 227-8		5
1134	In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys. 1990 , 1, 399-410		49
1133	Topical BCG for recurrent superficial bladder cancer. 1991 , 337, 821-822		11
1132	Scientific and ethical considerations in human gene therapy. 1991 , 5, 697-713		1
1131	Human rabies: strain identification reveals lengthy incubation. 1991 , 337, 822-823		2
1130	Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. 1991 , 64, 1037-46		349
1129	Gene therapy for cancer. 1991 , 27, 1069-70		7
1128	New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancer. 1991 , 27, 1168-72		11
1127	Gene transfer into vascular cells. 1991 , 17, 189B-194B		69
1126	Progress toward gene therapy. 1991 , 61, S47-55		14
1125	The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. 1991 , 139, 1-16		33
1124	News. 1991 , 2, 81-85		1
1123	Immunotherapy of Malignant Melanoma. 1991 , 9, 669-682		3

1122 Chapter 32. Perspectives on Human Gene Therapy. **1991**, 26, 315-319

1121 Clinical use of biologic response modifiers in cancer treatment: an overview. Part II. Colony-stimulating factors and interleukin-2. **1991**, 25, 490-8 13

1120 Lymphocytes as cellular vehicles for gene therapy in mouse and man. **1991**, 88, 3155-9 111

1119 Altered gene expression and oncogenesis of B-cell neoplasia. **1991**, 2, 335-42 9

1118 Important melanocytic lesions in childhood and adolescence. **1991**, 38, 791-809 23

1117 Immunotherapy. Neuroblastoma as a model. **1991**, 38, 425-41 19

1116 The scientific bases of cancer management: at the interface between fundamental research and clinical practice. **1991**, 117, 275-89 3

1115 Progress and challenges in the global effort against cancer. **1991**, 117, 290-4

1114 The prospects for therapy with tumour necrosis factors and their antagonists. **1991**, 9, 158-62 17

1113 Gene transfer into cardiac myocytes in vivo. **1991**, 1, 271-6 25

1112 Genome ethics treaty. **1991**, 352, 368

1111 Human tumor-infiltrating lymphocytes transfected with tumor necrosis factor gene could augment cytotoxicity to autologous tumor cells. **1991**, 82, 1203-6 8

1110 Correlation between class I antigen expression and the ability to generate tumour infiltrating lymphocytes from bladder tumour biopsies. **1991**, 64, 996-1000 7

1109 Engineering T lymphocyte antigen specificity. **1991**, 47, 306-10 5

1108 A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. **1991**, 68, 1694-5 25

1107 Surgeon's role in diagnostic advances. **1991**, 2, 83-5

1106 T cell targeting in cancer therapy. **1991**, 34, 1-8 27

1105 Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells. **1991**, 32, 342-52 26

1104	Selection of cytotoxic T lymphocytes against autologous human melanoma from lymph nodes with metastatic melanoma using repeated in vitro sensitization. 1991 , 9, 301-17	3
1103	Gene therapy techniques. 1991 , 2, 840-4	13
1102	Human autologous tumor-specific T cells in malignant melanoma. 1991 , 10, 151-76	32
1101	Towards Gene-Inhibition Therapy: A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic Acids and Ribozymes. 1991 , 2, 191-214	14
1100	Oncology. 1991 , 265, 3141	3
1099	Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. 1991 , 173, 647-58	332
1098	Medical Genetics. 1991 , 265, 3132	1
1097	Disseminated human malignant melanoma in congenitally immune-deficient (bg/nu/xid) mice. 1991 , 83, 350-5	13
1096	Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. 1991 , 11, 3374-8	160
1095	Regulatory concerns in human gene therapy. 1991 , 2, 243-9	20
1094	Clinical considerations in the design of protocols for somatic gene therapy. 1991 , 2, 77-83	17
1093	Safety issues related to retroviral-mediated gene transfer in humans. 1991 , 2, 5-14	184
1092	Gene transfer of adenosine deaminase into primitive human hematopoietic progenitor cells. 1991 , 2, 203-13	32
1091	Cutaneous melanoma. <i>New England Journal of Medicine</i> , 1991 , 325, 171-82	59.2 430
1090	Hepatocellular transplantation in acute hepatic failure and targeting genetic markers to hepatic cells. 1991 , 2, 331-58	24
1089	Positive selectable markers for use with mammalian cells in culture. 1991 , 2, 195-201	16
1088	Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog. 1991 , 83, 2007-11	138
1087	Human germ-line therapy: the case for its development and use. 1991 , 16, 593-612	40

1086 Allergy and Immunology. **1991**, 265, 3101

1085 DNA Technology in the Clinical Laboratory. **1992**, 23, 721-722

1084 Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. **1992**, 20, 1293-9 215

1083 Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies. **1992**, 8, 421-9 5

1082 Malignant melanoma. **1992**, 12, 338-45

1081 Progress and prospects for human cancer vaccines. **1992**, 84, 18-23 7

1080 Gene Therapy for Cancer. **1992**, 268, 2416 41

1079 Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. **1992**, 85, 1110-7 148

1078 Gene therapy and cancer: is it for everybody?. **1992**, 10, 607-9 3

1077 The immunology of HIV infection: implications for therapy. **1992**, 8, 1023-31 8

1076 Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: a model for gene therapy. **1992**, 89, 1138-42 108

1075 Transduction of primary human hepatocytes with amphotropic and xenotropic retroviral vectors. **1992**, 89, 8981-5 34

1074 Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. **1992**, 89, 1636-40 201

1073 Gene transfer into mammalian somatic cells in vivo. **1992**, 12, 335-56 57

1072 Retroviral vector-mediated gene transfer into hematopoietic cells: prospects and issues. **1992**, 1, 155-66 15

1071 Cytokines and cancer. **1992**, 305, 265-7 11

1070 Current issues in cancer. Biological therapy. **1992**, 304, 1621-3 2

1069 HTLV: non-HIV retroviruses of man. **1992**, 47, 371-6

1068	Cancer immunotherapy: are the results discouraging? Can they be improved?. 1992 , 59, 245-322	60
1067	Approaches to gene therapy of complex multigenic diseases: cancer as a model and implications for cardiovascular disease and diabetes. 1992 , 24, 411-7	9
1066	Aerosol gene delivery in vivo. 1992 , 89, 11277-81	232
1065	Experimental and clinical applications of molecular cell biology in nutrition and metabolism. 1992 , 16, 477-86	3
1064	Immunotherapy with sensitized lymphocytes. 1992 , 10, 357-69	21
1063	T-cell growth factors and the treatment of patients with cancer. 1992 , 62, S47-54	17
1062	Current status of interleukin-2 therapy in cancer. 1992 , 46, 473-84	31
1061	Gene therapy for cancer. 1992 , 339, 715-21	133
1060	New approaches in cancer pharmacology: Drug design and development. 1992 , 28, 1190-1200	11
1059	Gene therapy: present situation and future prospects. 1992 , 2, 75-83	3
1058	Phenotypic and functional analysis of tumour-infiltrating lymphocytes from patients with melanoma and other metastatic cancers. 1992 , 28, 345-50	10
1057	Clinical applications of interleukin-2. 1992 , 4, 229-46	3
1056	Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes. 1992 , 151, 139-47	6
1055	The use of parallel EEL spectral imaging and elemental mapping in the rapid assessment of anti-cancer drug localization. 1992 , 166, 367-80	9
1054	Gene therapy strategies for pulmonary disease. 1992 , 92, 44S-52S	39
1053	Divergent effects of TNF alpha in the adoptive immunotherapy of a murine sarcoma. 1992 , 53, 152-7	3
1052	Enzymes as agents for the treatment of disease. 1992 , 206, 45-76	22
1051	Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. 1992 , 10, 180-99	318

1050	The impact of molecular biology on the diagnosis and treatment of hemoglobin disorders. 1992 , 2, 1-38	2
1049	Therapy of Genetically Determined Metabolic Disorders. 1992 , 93-107	
1048	Human gene therapy comes of age. 1992 , 357, 455-60	786
1047	Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer. 1992 , 83, 1359-65	5
1046	Gene therapy for human inherited disorders: techniques and status. 1992 , 13, 33-54	18
1045	Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapy. 1992 , 12, 25-47	36
1044	Retroviral vectors for persistent expression in vivo. 1992 , 3, 540-7	30
1043	Propionate metabolism in cultured human cells after overexpression of recombinant methylmalonyl CoA mutase: implications for somatic gene therapy. 1992 , 18, 493-505	12
1042	Correction of methylmalonyl-CoA mutase deficiency in Mut0 fibroblasts and constitution of gene expression in primary human hepatocytes by retroviral-mediated gene transfer. 1992 , 18, 507-16	11
1041	Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases. 1992 , 1, 299-307	13
1040	Identification of a generalised packaging sequence for D-type retroviruses and generation of a D-type retroviral vector. 1992 , 189, 786-91	26
1039	Adoptive immunotherapy of cancer: biological response modifiers and cytotoxic cell therapy. 1992 , 5, 119-29	17
1038	Evaluation of basic procedures for adoptive immunotherapy for gastric cancer. 1992 , 5, 153-63	10
1037	Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study. 1992 , 4, 289-97	12
1036	New cytotoxic drugs and targets in oncology. 1992 , 14, 258-67	5
1035	Safety aspects of gene therapy. 1992 , 80, 421-6	42
1034	Abstracts of the State of the Art Symposia Presented at the 24th Congress of the International Society of Haematology, London, 23-27 August 1992. 1992 , 82, 181-271	
1033	Concepts and strategies for human gene therapy. 1992 , 208, 211-25	65

1032	Provocative gene therapy strategy for the treatment of hepatocellular carcinoma. 1992 , 16, 273-4	7
1031	Genetic correction of cultured T cells from an adenosine deaminase-deficient patient: characteristics of non-transduced and transduced T cells. 1992 , 22, 63-9	15
1030	Immunotherapy of colorectal cancer. 1992 , 70, 1425-33	19
1029	Nonsurgical management of recurrent colorectal cancer. 1993 , 71, 4278-92	24
1028	The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases. 1993 , 16, 1141-53	53
1027	Hepatic gene therapy: Present and future. 1993 , 18, 1263-1273	54
1026	CD8+ cytotoxic T cell therapy of cytomegalovirus and HIV infection. 1993 , 5, 484-91	39
1025	Lysosomal storage diseases: mechanisms of enzyme replacement therapy. 1993 , 25, 593-605	29
1024	Prospects for virus-based gene therapy for cystic fibrosis. 1993 , 25, 37-42	33
1023	Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing. 1993 , 67, 1223-8	12
1022	Lesion-specific activation of cloned human tumor-infiltrating lymphocytes by autologous tumor cells: induction of proliferation and cytokine production. 1993 , 101, 15-21	14
1021	Gene therapy for cancer. 1993 , 11, 197-201	17
1020	Neuroblastoma: the result of multistep transformation?. 1993 , 11, 276-82	18
1019	Generation of cytotoxic T lymphocytes from peripheral blood of leukaemic patients. 1993 , 37, 47-53	4
1018	Targeted inhibition of immunodeficiency virus replication in lymphocytes through retroviral mediated gene transfer. 1993 , 133, 407-21	10
1017	Molecular biology and therapy of disease. 1993 , 165, 720-7	3
1016	Human genetic therapy. 1993 , 14, 451-546	6
1015	Gene transfection of lung cells in vitro and in vivo. 1993 , 55, 181-207	9

1014	Recent advances in retrovirus vector technology. 1993 , 3, 102-9	60
1013	Increased viral titer through concentration of viral harvests from retroviral packaging lines. 1993 , 4, 609-15	77
1012	Cutaneous malignant melanoma. 1993 , 5, 7-41	3
1011	In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. 1993 , 4, 725-31	392
1010	Retroviral vector-mediated cytokine-gene transfer into tumor cells. 1993 , 11, 345-54	23
1009	Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. 1993 , 42, 250-7; discussion 257-8	79
1008	The future of therapy for glioblastoma. 1993 , 39, 538-43	45
1007	Gene transfer for therapy and prophylaxis of HIV-1 infection. 1993 , 685, 697-712	2
1006	Regulation of somatic-cell therapy and gene therapy by the food and drug administration. <i>New England Journal of Medicine</i> , 1993 , 329, 1169-73	59.2 109
1005	Gene therapy of the immune system. 1993 , 11, 297-329	73
1004	Human gene therapy. 1993 , 62, 191-217	294
1003	A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. 1993 , 4, 659-80	22
1002	Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer. 1993 , 4, 205-22	28
1001	Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. 1993 , 4, 703-11	55
1000	Retrovirus-mediated gene transfer into canine thyroid using an ex vivo strategy. 1993 , 4, 171-8	14
999	Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. 1993 , 4, 323-30	47
998	Immune-based therapeutics: scientific rationale and the promising approaches to the treatment of the human immunodeficiency virus-infected individual. 1993 , 17, 749-71	30
997	Retroviral vectors displaying functional antibody fragments. 1993 , 21, 1081-5	192

996	Somatic gene therapy. Methods for the present and future. 1993 , 119, 1100-7	13
995	Gene therapy. 1993 , 147, 1167-74	4
994	Pulmonary macrophages suppress the proliferation and cytotoxicity of tumor-infiltrating lymphocytes. 1993 , 8, 486-92	13
993	Autologous, orthotopic thyroid follicular cell transplantation: a surgical component of ex vivo somatic gene therapy. 1993 , 108, 51-62	10
992	IL-2 and gene-therapy of cancer. 1993 , 2, 1049-52	2
991	Myth of tumor immunology (review). 1993 , 3, 645-53	
990	Gene transfer into human hematopoietic progenitor cells: a review of current clinical protocols. 1993 , 2, 7-17	18
989	Infection of human cells with murine amphotropic replication-competent retroviruses. 1993 , 4, 579-88	50
988	Multiple Myeloma. 1993 , 269, 2412	8
987	Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. 1993 , 178, 361-6	213
986	Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. 1993 , 259, 1460-3	73
985	Breast cancer 2000 BC to 2000 AD--time for a paradigm shift?. 1993 , 32, 3-8	14
984	Molecular approaches to cancer therapy. 1993 , 61, 57-85	7
983	Interventional genetics and cancer treatment. 1993 , 306, 665-6	10
982	Bone Marrow Transplantation: A Review. 1993 , 2, 75-98	2
981	The development of gene therapy for the treatment of cancer. 1993 , 218, 455-63; discussion 463-4	53
980	Immunotherapy of melanoma: current status and prospects for the future. 1993 , 20, 65-73	3
979	Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. 1993 , 90, 11307-11	752

- 978 Embolisation therapy in the midgut carcinoid syndrome: just tumour ischaemia?. **1993**, 32, 251-6 9
- 977 Transplantation and Adoptive Cellular Therapy of Cancer: The Role of T-Cell Growth Factors. **1993**, 2, 33-47 1
- 976 New Molecular Targets and Therapeutic Strategies against Cancer. **1993**, 8, 1-7
- 975 Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. **1993**, 11, 652-60 42
- 974 Overview: In Vivo Expression of Human Genes. **1993**, 3, 1487-1498
- 973 Somatische Gentherapie in der Onkologie: Status quo und quo vadis. **1994**, 17, 91-101
- 972 Gene therapy in urological oncology: principles, strategies and potential. **1994**, 25, 177-82 15
- 971 Human gene therapy. **1994**, 4, 63-83 6
- 970 Modern chemotherapy in solid tumours. **1994**,
- 969 Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. **1994**, 5, 1357-70 21
- 968 Complex models for the study of gene function in cardiovascular biology. **1994**, 56, 741-61 50
- 967 The Polymerase Chain Reaction. **1994**, 104
- 966 Phase I study of immunotherapy of malignant melanoma by direct gene transfer. **1994**, 5, 1371-84 15
- 965 Carbohydrate receptor-mediated gene transfer to human T leukaemic cells. **1994**, 4, 429-35 40
- 964 Aminoglycoside 3'-phosphotransferase II (APH(3')II): Review of its safety and use in the production of genetically engineered plants. **1994**, 8, 137-165 33
- 963 Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors. **1994**, 102, 415-21 90
- 962 Consequences of stable transduction and antigen-inducible expression of the human interleukin-7 gene on tetanus-toxoid-specific T cells. **1994**, 5, 1457-66 7
- 961 Purified GPI-anchored CD4DAF as a receptor for HIV-mediated gene transfer. **1994**, 5, 1231-9 17

960	Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. 1994 , 5, 343-79	90
959	Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study. 1994 , 5, 1059-64	28
958	Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. 1994 , 5, 381-97	77
957	Study on contribution of genetically marked peripheral blood repopulating cells to hematopoietic reconstitution after transplantation. 1994 , 5, 1523-34	14
956	Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. 1994 , 5, 41-55	64
955	A nude rat model for neutron capture therapy of human intracerebral melanoma. 1994 , 28, 1079-88	27
954	Management of recurrent cutaneous melanoma. 1994 , 18, 143-86	10
953	Clonal dominance detected in metastases but not primary tumors of retrovirally marked human breast carcinoma injected into nude mice. 1994 , 12, 3-12	15
952	Human cancer and gene therapy. 1994 , 69, 273-9	10
951	Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells. 1994 , 39, 279-85	9
950	Immunocytotherapy. A new trend in fetal tissue transplantation. 1994 , 117, 411-414	1
949	Immunohistological analysis of anti-melanoma host responses. 1994 , 287, 28-35	17
948	From laboratory expertise to clinical practice: multidrug-resistance-based gene therapy becomes available for urologists. 1994 , 12, 104-11	9
947	Chemoresistance of renal cell carcinoma: 1986-1994. 1994 , 12, 214-23	16
946	From in vitro to in vivo. Progress in the use of cultured cells for human therapy. 1994 , 16, 189-94	2
945	Intelligent matrices for tumor-specific cytotoxic T lymphocytes. 1994 , 2, 61-65	
944	Antitumoral activity of an immunomodulatory fraction of <i>Nocardia opaca</i> : mechanism of action. 1994 , 16, 475-80	3
943	Metallothionein in carcinogenesis and cancer chemotherapy. 1994 , 25, 1297-310	34

942	Metastatic malignant melanoma of the oral cavity. A retrospective study. 1994 , 78, 51-6	41
941	Reactivation of murine tumour-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. 1994 , 3, 79-89	23
940	Retrovirus-mediated gene transfer in cancer therapy. 1994 , 63, 323-47	26
939	Human lung tumor cell secretion of interleukin-2 for protection against tumor engraftment. 1994 , 1, 229-35	3
938	Enhancement of T cell receptor signaling of tumor-infiltrating lymphocytes by retrovirally mediated fyn gene transduction. 1994 , 85, 1073-9	2
937	Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group. 1994 , 87, 293-300	24
936	Retroviral mediated gene transfer in chronic myelogenous leukaemia. 1994 , 87, 308-16	9
935	The new frontier: gene and oligonucleotide therapy. 1994 , 68, 145-59	49
934	The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy. 1994 , 716, 188-97; discussion 197-203	13
933	H-ras ribozyme-mediated alteration of the human melanoma phenotype. 1994 , 716, 242-53; discussion 253-6	25
932	Designing clinical trials of somatic gene therapy. 1994 , 716, 283-92; discussion 292-3	3
931	Gene therapy for urologic cancer. 1994 , 44, 617-24	9
930	Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. 1994 , 5, 667-77	35
929	Expression of tumour necrosis factor-alpha, -beta and interferon-gamma genes within human neuroglial tumour cells and brain specimens. 1994 , 6, 171-80	38
928	Recombinant interleukin-2 in cancer: basic and clinical aspects. 1994 , 20, 275-311	16
927	Adoptive cellular therapy of urological neoplastic disease. 1994 , 20, 173-90	1
926	Gene therapy--its potential in the management of oral cancer. 1994 , 30B, 143-54	13
925	Adoptive Immunotherapy of Cancer. 1994 , 2, 13-22	3

924	Immunotherapy for cancer by direct gene transfer into tumors. 1994 , 5, 57-77	83
923	Improved methods of retroviral vector transduction and production for gene therapy. 1994 , 5, 19-28	359
922	Melanoma vaccines. Current status and future prospects. 1994 , 47, 373-82	12
921	Gene transfer in tumor therapy. 1994 , 5, 789-94	14
920	Organ-Specific Targeting of Synthetic and Natural Drug Carriers. 1994 , 9, 263-282	4
919	Expansion of activated lymphocytes obtained from renal cell carcinoma in an automated hollow fiber bioreactor. 1994 , 3, 263-71	13
918	Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. 1994 , 91, 7889-93	15
917	Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. 1994 , 91, 4318-22	165
916	Gene therapy for adenosine deaminase deficiency. 1995 , 51, 72-81	24
915	Retroviruses as vectors. 1995 , 51, 12-30	81
914	Gene therapy for solid tumors. 1995 , 51, 192-204	21
913	Replication-competent and -defective retrovirus vectors for oncogenic studies. 1995 , 254, 206-28	2
912	Gene transfer as cancer therapy. 1995 , 58, 417-54	109
911	Basic principles associated with gene therapy of cancer. 1995 , 4, 125-37	4
910	Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. 1995 , 103, 5-28	
909	Studies of in vivo recruitment and activation of cytotoxic lymphocytes using a gelatin-sponge model of concomitant tumor immunity. 1995 , 62, 421-7	3
908	Endogenous D-factor activity partially mediates the toxic but not the therapeutic effects of tumor necrosis factor. 1995 , 63, 245-9	2
907	Generation of cytotoxic effector cells against human melanoma. 1995 , 40, 397-409	1

906	Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine. 1995 , 5, 401-410	2
905	Gene therapy on renal-cell carcinoma: magic bullet or tragic insanity?. 1995 , 13, 178-85	4
904	Cancer gene therapy: principles, problems, and perspectives. 1995 , 73, 157-63	35
903	Marker gene transfer into leukapheresis preparations containing hematopoietic progenitor cells: application in high-dose therapy rescued by reinfusion of peripheral blood hematopoietic progenitors in patients with multiple myeloma. 1995 , 73, 197-203	2
902	Retroviral transfer of HSV1-TK gene into human lung cancer cell line. 1995 , 73, 107-12	8
901	Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. 1995 , 1, 267-71	86
900	Gene therapy: from fiction to factual tool?. 1995 , 7, 4-6	
899	Activation of the anti-tumor effector cells by Radix bupleuri. 1995 , 30, 79-87	23
898	Gene-modified cells for the treatment of cancer. 1995 , 66, 175-90	7
897	Retroviral vectors directed to predefined cell types for gene therapy. 1995 , 23, 5-12	9
896	Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. 1995 , 6, 565-73	186
895	Gene therapy in mental retardation: ethical considerations. 1995 , 1, 7-13	4
894	Retroviral transfer of the multidrug resistance-1 gene into lineage-committed and primitive hemopoietic cells. 1995 , 13 Suppl 3, 93-9	7
893	Breast Cancer: A Revolutionary Concept. 1995 , 2, 9-18	13
892	Gentherapie in der Onkologie: Perspektiven, Chancen und Risiken. 1995 , 18, 16-26	
891	Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. 1995 , 13, 410-8	45
890	Synthetic Vascular Grafts Seeded with Genetically Modified Endothelium in the Dog: Evaluation of the Effect of Seeding Technique and Retroviral Vector on Cell Persistence in Vivo. 1995 , 4, 219-235	11
889	Gene Therapy Approaches in Urologic Oncology. 1995 , 4, 203-218	8

888	Cellular Gene Therapy. 1995 , 9, 91-114	6
887	The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. 1995 , 6, 927-39	44
886	Novel cellular therapies. 1995 , 24, 411-20	2
885	Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study. 1995 , 6, 195-204	29
884	Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector. 1995 , 6, 1379-89	6
883	The metabolism service. 1995 , 13, 637-45	
882	In vivo gene transfer: a potential approach for immunotherapy. 1995 , 14, 135-7	
881	Receptor-mediated gene transfer into human T lymphocytes via binding of DNA/CD3 antibody particles to the CD3 T cell receptor complex. 1995 , 6, 753-61	98
880	Biological therapy in the treatment of cancer. 1995 , 4, 869-72, 889-91	1
879	Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. 1995 , 18, 139-46	23
878	Immunologic host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. 1995 , 105, 110S-116S	12
877	Advances in cancer gene therapy. 1995 , 32, 289-341	20
876	Current therapy for cutaneous melanoma. 1995 , 32, 689-707; quiz 708-9	136
875	Evolution of clinical agents for ovulation induction. 1995 , 172, 753-9	7
874	Direct gene transfer for treatment of human cancer. 1995 , 772, 227-31	29
873	Transfer of genes to humans: early lessons and obstacles to success. 1995 , 270, 404-10	935
872	Autologous bone marrow transplantation. 1995 , 32, 67-119	
871	Gene therapy vectors as drug delivery systems. 1995 , 28, 181-9	24

870	Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. 1995 , 6, 1231-55	47
869	IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. 1995 , 6, 1607-24	60
868	Virus vector design in gene therapy. 1995 , 1, 410-7	42
867	T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. 1995 , 270, 475-80	1121
866	Immunotherapy of malignant melanoma. 1996 , 76, 1355-81	11
865	Gene transfer into hematopoietic stem cells. 1996 , 17, 129-136	1
864	Genetic allogeneization of malignant melanoma. 1996 , 17, 169-174	5
863	Therapeutic potential of retroviral vectors. 1996 , 17, 7-14	10
862	Gene therapy. 1996 , 33, 961-1041	9
861	In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction. 1996 , 218, 164-70	14
860	Background and update to a phase I trial of stem cell gene marking in multiple myeloma. 1996 , 17, 175-184	1
859	Update on the Role of Immunotherapy in the Management of Kidney Cancer. 1996 , 3, 536-541	11
858	The potential applications of gene transfer in the treatment of patients with cancer: a concise review. 1996 , 14, 343-52	9
857	Ethical Issues of Perinatal Human Gene Therapy. 1996 , 5, 232-244	
856	Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. 1996 , 93, 15388-93	212
855	Vectors and target cells for gene therapy of blood diseases. 1996 , 6, 25-30	2
854	Measuring success in clinical gene therapy research. 1996 , 2, 234-6	8
853	Retroviral vectors. From laboratory tools to molecular medicine. 1996 , 5, 139-58	49

852	Current status of adoptive immunotherapy of cancer. 1996 , 22, 213-28	37
851	Cancer and gene therapy. 1996 , 73, 207-18	9
850	Current status and future prospects of human gene therapy. 1996 , 38, 176-81	0
849	The maturation of human gene therapy. 1996 , 85, 1261-5	12
848	Immunotherapy and gene transfer in the treatment of the oncology patient: role of transfusion medicine. 1996 , 10, 1-14	2
847	Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. 1996 , 65, 413-21	127
846	T-cell gene therapy. 1996 , 7, 629-34	18
845	Gene therapy in pediatric oncology. 1996 , 14, 87-99	1
844	T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. 1996 , 2, 216-23	517
843	Peptide-displaying phages for targeted gene delivery?. 1996 , 2, 276-7	8
842	Progress in human gene therapy. 1996 , 49, 1791-4	10
841	HSV-tk gene therapy in head and neck squamous cell carcinoma. Enhancement by the local and distant bystander effect. 1996 , 122, 746-9	36
840	{BLR 2219} Gene Therapy - NIH. 1996 , 15, 171-196	
839	Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. 1996 , 7, 1415-22	69
838	Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. 1996 , 7, 1281-306	58
837	Gene marking. 1996 , 7, 1927-36	41
836	A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins. 1996 , 7, 367-400	12
835	Gene therapy in the United States: a five-year status report. 1996 , 7, 1781-90	92

834	Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. 1996 , 7, 1323-9	35
833	Gene therapy in gastroenterology. 1996 , 38, 161-5	6
832	Use of a retroviral vector to study the trafficking patterns of purified ovarian tumor infiltrating lymphocytes (TIL) used in intraperitoneal adoptive immunotherapy of ovarian cancer patients. A pilot study. 1996 , 7, 1351-65	3
831	Determination of tissue distribution of an intramuscular plasmid vaccine using PCR and in situ DNA hybridization. 1996 , 7, 2185-94	62
830	Fetal somatic gene therapy. 1996 , 2, 633-41	19
829	Inhibition of B16 melanoma metastasis by the immunomodulator AS101. 1996 , 9, 319-25	1
828	Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II). 1996 , 7, 537-49	30
827	Section Review Oncologic, Endocrine & Metabolic: Gene therapy for cancer therapeutics. 1996 , 6, 1267-1284	3
826	Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease. 1997 , 8, 2143-60	21
825	Gene therapy for neurologic disease: benchtop discoveries to bedside applications. 2. The bedside. 1997 , 12, 77-84	2
824	Human gene therapy: principles and modern advances. 1997 , 3, 59-110	1
823	A simple human immunodeficiency virus vector system for selective infection of CD4(+) cells and inducible expression of foreign genes. 1997 , 29, 103-110	
822	Cytokine gene transduction in the immunotherapy of cancer. 1997 , 40, 259-307	36
821	Gene therapy approaches to enhance antitumor immunity. 1997 , 40, 309-37	7
820	Interleukin-2. 1997 , 2, 1-47	
819	Gene therapy for neurologic disease: benchtop discoveries to bedside applications. 1. The bench. 1997 , 12, 1-12	6
818	Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. 1997 , 8, 615-24	74
817	Gene therapy. Is the future here yet?. 1997 , 24, 179-99	8

816	T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. 1997 , 113, 1163-70	59
815	Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma. 1997 , 157, 2396-401	7
814	Genetic therapy. Past, present, and future. 1997 , 44, 153-78	13
813	Advances in dermatologic surgery. 1997 , 15, 9-18	6
812	Immunotherapy and gene therapy for renal cell carcinoma. 1997 , 3, 148-53	1
811	Gene therapy: current and future implications for oncology nursing practice. 1997 , 13, 115-22	6
810	Mechanism of trapping of intravenously transplanted lymphocytes in the liver. 1997 , 29, 2010-1	
809	Regulating biotechnology: a rational-political model of policy development. 1997 , 40, 115-38	7
808	The role of adoptive immunotherapy in solid cancers. 1997 , 50, 47-68	5
807	Urotherapy for patients with cancer. 1997 , 48, 309-15	4
806	Tracking and quantitation of retroviral-mediated transfer using a completely humanized, red-shifted green fluorescent protein gene. 1997 , 22, 162-7	40
805	Recent Advances in the Treatment of Malignant Melanoma with Gene Therapy. 1997 , 3, 636-651	4
804	Current challenges in cancer gene therapy. 1997 , 242, 109-114	9
803	Thymidine Kinase (TK) Gene-Transduced Human Lymphocytes Can Be Highly Purified, Remain Fully Functional, and Are Killed Efficiently With Ganciclovir. 1997 , 89, 1334-1340	77
802	Placental and/or Umbilical Cord Blood: An Alternative Source of Hematopoietic Stem Cells for Transplantation. 1997 , 90, 4665-4678	348
801	Gene therapy for prostate cancer. 1997 , 79 Suppl 2, 64-8	18
800	Therapy with cultured T cells: principles revisited. 1997 , 157, 177-94	72
799	Gene therapy strategies for leukemia. 1997 , 3, 39-46	7

798	Differentiation, differentiation/gene therapy and cancer. 1997 , 73, 51-65	40
797	Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer. 1997 , 20, 742-54	12
796	Gene therapy strategies for carcinoma of the breast. 1997 , 44, 93-114	14
795	Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes. 1997 , 32, 29-38	7
794	In vivo distribution and gene expression of genetically modified hepatocytes after intrasplenic transplantation. 1997 , 40, 554-60	5
793	Computed tomography in staging of patients with melanoma metastatic to the regional nodes. 1997 , 4, 396-402	50
792	Gene therapy in surgery: Part II: Application to septic shock and to organ transplantation. 1997 , 29, 22-26	2
791	Prospects for adoptive T cell therapy. 1997 , 9, 702-8	110
790	Retroviral gene therapy in hematopoietic diseases. 1997 , 12, 187-93	3
789	Efficient transfer of oligonucleotides and plasmid DNA into the whole heart through the coronary artery. 1998 , 5, 1472-80	17
788	Enhanced gene expression in mouse lung by prolonging the retention time of intravenously injected plasmid DNA. 1998 , 5, 1531-7	79
787	Gene therapy for tissue repair and regeneration. 1998 , 33, 53-69	79
786	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. 1998 , 103, 449-61	21
785	Cardiovascular gene therapy. 1998 , 7, 114-120	
784	Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. 1998 , 9, 53-62	24
783	Treatment of adenosine deaminase deficiency. 1998 , 9, 87-93	2
782	Gene therapy for cardiovascular diseases. 1998 , 8, 509-520	4
781	Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. 1998 , 9, 1627-42	29

780	Relevance of the immune system in human urological malignancies: prospective for future clinical treatments. 1998 , 51, 41-9	5
779	Gene therapy for melanoma in humans. 1998 , 12, 519-38	9
778	Internal resection of posterior uveal melanomas. 1998 , 82, 1147-53	39
777	T cell activation modulates retrovirus-mediated gene expression. 1998 , 9, 1457-67	45
776	Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. 1998 , 9, 1769-74	167
775	A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. 1998 , 9, 2407-25	128
774	Current status of gene marking and gene therapy in oncology clinical trials. 1998 , 166-199	
773	Gene transfer: a review of methods and applications. 1998 , 30, 335-47	45
772	Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. 1998 , 95, 1201-6	117
771	Cancer Gene Therapy. 1998 , 7, 421-469	19
770	Cytokine Gene Therapy for Human Tumors. 1998 , 7, 537-563	7
769	Cancer Chemotherapy Using Suicide Genes. 1998 , 7, 505-536	45
768	Gene Therapy for Lung Cancer. 1999 , 30, 280-289	
767	Natural killer cell-mediated lysis of autologous cells modified by gene therapy. 1999 , 189, 1855-62	31
766	Cancer gene therapy update. 1999 , 5, 7-21	
765	Advances in cancer gene therapy. 1999 , 9, 711-735	2
764	Gene transfer technology in therapy: current applications and future goals. 1999 , 17, 191-202	72
763	Recent progress in gene transfer into hematopoietic stem cells. 1999 , 30, 143-58	7

762	The use of biological therapy in cancer of the head and neck. 1999 , 23, 106-34	7
761	How realistic is cutaneous gene therapy?. 1999 , 8, 419-31	15
760	Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. 1999 , 90, 536-45	46
759	Beta-galactosidase marker genes to tag and track human hematopoietic cells. 1999 , 6, 3-13	9
758	Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. 1999 , 81, 1009-16	187
757	Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes. 1999 , 24, 1043-51	5
756	Altered replication of human immunodeficiency virus type 1 (HIV-1) in T cell lines retrovirally transduced to express Herpesvirus saimiri proteins StpC and/or Tip. 1999 , 264, 125-33	12
755	Molecular intensive care medicine. 1999 , 25, 652-61	5
754	Towards metabolic sink therapy for mut methylmalonic acidaemia: correction of methylmalonyl-CoA mutase deficiency in T lymphocytes from a mut methylmalonic acidaemia child by retroviral-mediated gene transfer. 1999 , 22, 773-87	7
753	Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer. 1999 , 5, 3-15	18
752	Interleukin-10: a cytokine used by tumors to escape immunosurveillance. 1999 , 16, 86-94	81
751	T cell-based immunotherapy for cancer: a virtual reality?. 1999 , 49, 74-100, 65	9
750	Gene therapy for cancer. 1999 , 35, 867-85	44
749	Gene therapy for cancer. 1999 , 35, 2039-57	43
748	La toxicologie de la th�rapie g�n�ique. 1999 , 1999, 31-35	
747	Th�rapie g�n�ique des dystrophies musculaires. 1999 , 10, 327-338	
746	Th�rapie g�n�ique en cancérologie : l'attente des r�sultats cliniques. 1999 , 10, 313-325	
745	Gene therapy of arthritis. 1999 , 38, 233-9	43

744	Gene therapy: lessons learnt from the past decade. Interview by Clare Thompson. 1999 , 319, 1310	9
743	Use of codon-modified, red-shifted variants of green fluorescent protein genes to study virus-mediated gene transfer. 1999 , 302, 424-37	
742	Gene Therapy for Hematological Disorders. 133-152	
741	In Vivo Persistence of Donor Cells following Adoptive Transfer of Allogeneic Dendritic Cells in HIV-Infected Patients. 2000 , 9, 307-317	13
740	Gene therapy of brain tumors: problems presented by physiological barriers. 2000 , 8, 1-7	3
739	Developments in gene therapy for muscular dystrophy. 2000 , 48, 223-38	53
738	Progress in antiangiogenic gene therapy of cancer. 2000 , 89, 1181-1194	89
737	Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules. 2000 , 56, 19-29	1
736	Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide. 2000 , 22, 659-71	9
735	Gene therapy scores against cancer. 2000 , 6, 862-3	39
734	Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. 2000 , 7, 596-604	79
733	Long-term silencing of retroviral vectors is resistant to reversal by trichostatin A and 5-azacytidine. 2000 , 7, 653-63	34
732	Retroviral-mediated gene transfer in primary murine and human T-lymphocytes. 2000 , 15, 133-42	19
731	Gene therapy for brain tumors. 2000 , 2, 463-72	27
730	Gene therapy--when a simple concept meets a complex reality. Review on gene therapy. 2000 , 1, 142-5	7
729	Herpesvirus saimiri-transformed macaque T cells are tolerated and do not cause lymphoma after autologous reinfusion. 2000 , 95, 3256-3261	32
728	Retroviral vectors. 2000 , 53, 173-6	38
727	Biological Therapy of Breast Cancer. 2000 , 14, 221-246	7

726	Potential applications of gene therapy in the patient with cancer. 2000 , 17, 121-32	5
725	Viral vectors for gene transfer: a review of their use in the treatment of human diseases. 2000 , 60, 249-71	288
724	Gene therapy for the treatment of cancer. 2001 , 16, 275-88	12
723	Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. 2001 , 98, 220-8	78
722	Cancer Gene Therapy. 2001 , 457-496	
721	Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. 2001 , 24, 363-73	304
720	MHC Class II Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design. 2001 , 24, 195-204	30
719	Genetic approaches for antigen-selective cell therapy. 2001 , 1, 385-97	29
718	T lymphocytes as targets of gene transfer with Moloney-type retroviral vectors. 2001 , 1, 325-37	6
717	Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. 2001 , 167, 6356-65	92
716	Gene transfer for cerebrovascular disease. 2001 , 3, 10-6	33
715	Introduction. 2001 , 249, 327-8	1
714	In vivo tracking of tumor-specific T cells. 2001 , 13, 141-6	56
713	Migration of naive, effector and memory T cells: implications for the regulation of immune responses. 2001 , 184, 20-37	50
712	Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future perspectives. 2001 , 187, 22-36	216
711	Prospects for prenatal gene therapy in disorders causing mental retardation. 2001 , 7, 65-72	9
710	Lysine: Is it worth more?. 2001 , 36, 3-32	19
709	Gene-marking studies of hematopoietic cells. 2001 , 73, 14-22	10

708	Gene-based cancer vaccines: an ex vivo approach. 2001 , 15, 545-58		31
707	Gene therapy: principles and applications to hematopoietic cells. 2001 , 15, 523-44		31
706	Gene expression and gene therapy in experimental duodenal ulceration. 2001 , 95, 325-35		12
705	Strategies to restore p53 function in patients with lung cancer. 2001 , 3, 99-101		6
704	Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. 2001 , 93, 1014-20		47
703	Recent developments in retroviral gene delivery systems. 2001 , 1, 911-3		3
702	Cellular therapy of cancer with natural killer cells: will it ever work?. 2001 , 10, 23-6		9
701	Informing the public about advances in cancer therapy. 2002 , 11, 25-32		3
700	Gene therapy and molecular immunology unite to give new life to cancer immunotherapy. <i>Molecular Therapy</i> , 2002 , 5, 665-7	11.7	4
699	Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. 2002 , 9, 527-35		60
698	Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. 2002 , 298, 850-4		2293
697	Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. 2002 , 169, 4811-21		40
696	Biodistribution and retention time of retrovirally labeled T lymphocytes in mice is strongly influenced by the culture period before infusion. 2002 , 25, 385-95		8
695	pa317 Retrovirus Packaging Cells. <i>Molecular Therapy</i> , 2002 , 6, 572-575	11.7	3
694	Informing the public about advances in cancer therapy. 2002 , 11, 25-32		
693	Advances in gene therapy for malignant melanoma. 2002 , 9, 39-48		17
692	pa317 Retrovirus Packaging Cells. <i>Molecular Therapy</i> , 2002 , 6, 572-575	11.7	5
691	Gene therapy and reproductive medicine. 2002 , 77, 645-57		18

690	Current status of adoptive immunotherapy of malignancies. 2002 , 2, 237-47	17
689	[Cancer genetic immunotherapy]. 2002 , 9, 301-21	1
688	Disease genes: flattery and deception. 2002 , 23, 504-9	1
687	Introduction to cancer gene therapy. 2002 , 11, 497-519, v	19
686	Viruses in the treatment of brain tumors. 2002 , 12, 553-70	7
685	Molecular Genetic Imaging: A Nuclear Medicine Based Perspective. <i>Molecular Imaging</i> , 2002 , 1, 153535003002021	1
684	Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer. 2002 , 2, 91-100	17
683	Cancer gene therapy: 'delivery, delivery, delivery'. 2002 , 7, d1516	10
682	Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. 2002 , 99, 149-53	71
681	Post-transduction events in retrovirus-mediated gene therapy involving hematopoietic stem cells: beyond efficiency issues. 2002 , 38, 46-54	3
680	Cancer gene therapy state-of-the-art. 2002 , 7, 149-155	3
679	Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance?. 2002 , 41, 241-50	21
678	Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model. 2002 , 21, 3274-83	26
677	Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. 2002 , 20, 143-8	339
676	Dual-specific T cells combine proliferation and antitumor activity. 2002 , 20, 1221-7	90
675	A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. 2003 , 27, 341-56	26
674	Cancer immunogene therapy: a review. 2003 , 10, 37-43	12
673	Sequences within both the 5' untranslated region and the gag gene are important for efficient encapsidation of Mason-Pfizer monkey virus RNA. 2003 , 309, 166-78	18

672	Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy. 2003 , 1640, 1-24		48
671	Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity. 2003 , 58, 33-42		8
670	Recombinant Sendai virus vectors for activated T lymphocytes. 2003 , 10, 1381-91		23
669	Adoptive-cell-transfer therapy for the treatment of patients with cancer. 2003 , 3, 666-75		526
668	Reproductive tract gene transfer. 2003 , 80, 475-84		19
667	Breakthroughs in cancer gene therapy. 2003 , 19, 217-26		2
666	HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. 2003 , 106, 16-22		57
665	Assessing gene and cell therapies applied in striated skeletal and cardiac muscle: is there a role for nuclear magnetic resonance?. 2003 , 13, 397-407		5
664	Is retroviral gene marking too dangerous to use?. 2003 , 5, 190-3		14
663	Monitoring of developing graft-versus-host disease mediated by herpes simplex virus thymidine kinase gene-transduced T cells. 2003 , 14, 341-51		5
662	Autologous cancer vaccine: a novel formulation. 2003 , 47, 255-63		9
661	Non-viral gene transfer therapy for cystic fibrosis. 2003 , 3, 449-58		26
660	American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. <i>Molecular Therapy</i> , 2003 , 8, 180-7	11.7	129
659	Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. 2003 , 14, 1089-105		43
658	Immunology and Immunotherapy of Head and Neck Cancer. 2003 , 569-591		1
657	Genetic Engineering of Targeted Retroviral Vectors. 2003 , 293-320		1
656	Molecular-genetic imaging: current and future perspectives. 2003 , 111, 1620-9		122
655	Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. 2004 , 64, 6783-90		105

654	Cancer gene therapy Current status in the clinics. 2004 , 2, 219-274	3
653	Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. 2004 , 173, 7125-30	402
652	Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. 2004 , 101 Suppl 2, 14639-45	289
651	Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2004 ,	7
650	Genetic, cellular and immune approaches to disease therapy: past and future. 2004 , 10, 135-41	65
649	Development of effective immunotherapy for the treatment of patients with cancer. 2004 , 198, 685-96	42
648	Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. 2004 , 56, 1193-204	135
647	Gene therapy clinical trials worldwide 1989-2004-an overview. 2004 , 6, 597-602	306
646	Human cancer gene therapy with cytokine gene-modified cells. 2004 , 4, 1595-607	16
645	Genetic modification of T lymphocytes for adoptive immunotherapy. <i>Molecular Therapy</i> , 2004 , 10, 5-18 11.7	70
644	Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. 2004 , 103, 1261-9	56
643	From bench to bedside for gene-directed enzyme prodrug therapy of cancer. 2005 , 16, 349-59	93
642	Gene Therapy and Gene Delivery Systems as Future Human Therapeutics. 1-5	1
641	T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!. 2005 , 35, 935-42	38
640	Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer. 2005 , 96, 643-50	7
639	A concise peer into the background, initial thoughts and practices of human gene therapy. 2005 , 27, 506-17	16
638	Immunotherapy for cancer. 1991 , 78, 1281-2	6
637	Cytokines in tumour therapy. 1992 , 79, 990-7	29

636	Gene transfer therapy in cancer. 1993 , 80, 566-72	24
635	A QSAR-modeling perspective on cationic transfection lipids. 1. Predicting efficiency and understanding mechanisms. 2005 , 7, 1023-34	27
634	Immunotherapy for melanoma: the good, the bad, and the future. 2005 , 7, 383-92	8
633	Lessons for the stem cell discourse from the gene therapy experience. 2005 , 48, 585-91	10
632	Bcl-2 overexpression enhances tumor-specific T-cell survival. 2005 , 65, 2001-8	109
631	Animal models for growth hormone gene therapy. 2005 , 5, 493-509	6
630	Autologous formalin-fixed tumor vaccine. 2005 , 11, 1181-8	14
629	Folate-linked lipid-based nanoparticle for targeted gene delivery. 2005 , 2, 243-52	48
628	Retroviral vector production in the National Gene Vector Laboratory at Indiana University. 2005 , 12 Suppl 1, S28-35	17
627	Current status of gene therapy strategies to treat HIV/AIDS. <i>Molecular Therapy</i> , 2005 , 11, 823-42	11.7 81
626	Cell-Specific Targeting of Lipid-Based Carriers for ODN and DNA. 2005 , 15, 59-92	13
625	[Gene therapy and the skin]. 2005 , 132, 154-63	1
624	Current status of genetic modification of T cells for cancer treatment. 2005 , 7, 262-72	14
623	Cell-specific targeting of lipid-based carriers for ODN and DNA. 2005 , 15, 59-92	26
622	Polymers for DNA delivery. 2005 , 10, 34-64	157
621	Adoptive T-cell therapy of cancer. 2006 , 20, 711-33	14
620	Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?. 2006 , 3, 668-81	258
619	Clinical application of expanded CD4+25+ cells. 2006 , 18, 78-88	83

618 New Technologies in Cardiovascular Research: Gene Therapy. **2006**, 85-101

617 Adoptive cellular immunotherapy. 648-660

616 Gene transfer: methods and applications. 661-678

615 Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells. **2006**, 213-233

614 Cancer gene therapy: the power of negative thinking. **2006**, 13, 191-3

2

613 High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes: prospects for an animal model of cutaneous gene therapy. **2006**, 34, 239-45

9

612 Targeted tumor cell death induced by autologous tumor-specific T lymphocyte recognition of wild-type p53-derived peptides. **2006**, 76, 99-104

611 T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. **2006**, 55, 1142-50

19

610 The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. **2007**, 56, 70-80

23

609 Gene therapy works in animal models of rheumatoid arthritis...so what!. **2006**, 8, 386-93

7

608 Towards immunogene therapy of hematological malignancies. **2006**, 34, 251-63

0

607 Growth inhibition of intracerebral rat glioma by transfection-induced human interferon-beta. **1995**, 59, 105-9

11

606 Improving T cell therapy for cancer. **2006**, 6, 215-29

19

605 Radiation-guided gene therapy of cancer. **2006**, 5, 437-44

5

604 Vascular Embolotherapy. **2006**,

3

603 Immunotherapy of melanoma: a critical review of current concepts and future strategies. **2007**, 7, 345-58

41

602 Immune responses to gene-modified T cells. **2007**, 7, 361-8

10

601 Foxp3-expressing CD4(+)T cells under the control of INF-gamma promoter prevent diabetes in NOD mice. *Molecular Therapy*, **2007**, 15, 1551-7

11.7 11

600	The continuing contribution of gene marking to cell and gene therapy. <i>Molecular Therapy</i> , 2007 , 15, 666-767	19
599	T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy. 2007 , 7, 893-906	13
598	Immunologic approaches to ovarian cancer treatment. 2007 , 25, 2884-93	39
597	Emerging Therapeutic Concepts III: Chimeric Immunoglobulin T Cell Receptors, T-Bodies. 533-571	
596	Development of targeted gene transfer into human primary T lymphocytes and macrophages using high-titer recombinant HIV vectors. 2007 , 129, 532-8	8
595	Gene Therapy for Cancer. 2007 ,	3
594	Gene therapy. 2007 , 9, 519-20	
593	Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. 2007 , 25, 1618-26	138
592	Targeting the tumor microenvironment. 2007 , 12, 3468-74	158
591	Gene therapy: the first two decades and the current state-of-the-art. 2007 , 213, 301-5	96
590	Gene therapy clinical trials worldwide to 2007--an update. 2007 , 9, 833-42	459
589	Amphiphilic polyether branched molecules to increase the circulation time of cationic particles. 2007 , 15, 3176-86	8
588	Cellular therapies: a Canadian blood services research and development symposium. 2007 , 21, 317-36	6
587	Encapsulation of nucleic acids and opportunities for cancer treatment. 2007 , 24, 618-27	31
586	What is the status of gene therapy for primary immunodeficiency?. 2007 , 38, 274-84	7
585	The T-body approach: redirecting T cells with antibody specificity. 2008 , 329-42	83
584	Manipulation of MHC-I/TCR interaction for immune therapy. 2008 , 5, 171-82	8
583	Adoptive cell transfer: a clinical path to effective cancer immunotherapy. 2008 , 8, 299-308	1179

582	Insertional mutagenesis and clonal dominance: biological and statistical considerations. 2008 , 15, 143-53		41
581	Tissue engineering for bone defect healing: an update on a multi-component approach. 2008 , 39 Suppl 2, S9-20		157
580	Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. 2008 , 127, 66-77		27
579	Gene Therapy Protocols. 2008 ,		
578	A microfluidic bioreactor for increased active retrovirus output. 2008 , 8, 75-80		21
577	Arthritis gene therapy's first death. 2008 , 10, 110		70
576	A review of current progress in gene and stem cell therapy for erectile dysfunction. 2008 , 8, 1521-38		12
575	Gene therapy: some history, applications, problems, and prospects. 2008 , 36, 97-103		80
574	Development of peptide-targeted lipoplexes to CXCR4-expressing rat glioma cells and rat proliferating endothelial cells. <i>Molecular Therapy</i> , 2008 , 16, 516-24	11.7	18
573	Gene therapy: targeting the myocardium. 2008 , 94, 89-99		78
572	Melanoma. 2008 ,		1
571	Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. 2008 , 26, 2292-8		95
570	Current status of gene therapy in Asia. <i>Molecular Therapy</i> , 2008 , 16, 237-43	11.7	21
569	Optimizing gene delivery vectors for the treatment of heart disease. 2008 , 8, 911-22		42
568	Development of gene therapy for blood disorders. 2008 , 111, 4431-44		57
567	Gene Therapy. 2008 , 1		
566	Genetically Modified T Cells for Human Gene Therapy. 193-205		
565	Arthritis gene therapy at an inflection point. 2008 , 3, 207-210		7

564	Introduction: immunity, diagnosis, vector, and beneficial uses of neurotropic viruses. 263-264		
563	Viral gene therapy for central nervous system diseases. 424-434		
562	A role for adeno-associated viral vectors in gene therapy. 2008 , 31, 1-11		13
561	. 2008 ,		
560	Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. 2009 , 63		
559	Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". 2009 , 20, 1229-39		67
558	Gene therapy and informed consent decision making: nursing research directions. 2009 , 11, 98-107		2
557	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. 2009 , 1, 845-53		13
556	Inhibition of multidrug-resistant <i>Acinetobacter baumannii</i> by nonviral expression of hCAP-18 in a bioengineered human skin tissue. <i>Molecular Therapy</i> , 2009 , 17, 562-9	11.7	32
555	Towards therapy of Gaucher's disease by gene transfer into hematopoietic cells. 1994 , 53, 253-64		8
554	Gene transfer to hematopoietic cells--the clinical experience. 1997 , 59, 67-75		17
553	Adoptive cell therapy for the treatment of patients with metastatic melanoma. 2009 , 21, 233-40		466
552	Cytokine gene transfer in cancer therapy. 1998 , 16 Suppl 1, 251-60		11
551	Viral vectors: from virology to transgene expression. 2009 , 157, 153-65		224
550	Engineering lymphocyte subsets: tools, trials and tribulations. 2009 , 9, 704-16		156
549	Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus. 2010 , 19, e56-66		15
548	Ligand-directed cancer gene therapy to angiogenic vasculature. 2009 , 67, 103-121		5
547	Preface. Gene transfer into hematopoietic cells: from basic science to clinical application. 2009 , 506, v-xi		2

546	Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: advances in hepatocyte transplantation and retroviral vectors. 2009 , 9, 136-49	28
545	Adoptive cell therapy: genetic modification to redirect effector cell specificity. 2010 , 16, 336-41	74
544	Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. 2010 , 116, 1035-44	237
543	Genetic modification of T cells improves the effectiveness of adoptive tumor immunotherapy. 2010 , 58, 347-54	2
542	Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview. 2010 , 27, 1487-97	37
541	Gene therapy in autoimmune diseases: challenges and opportunities. 2010 , 9, 170-4	16
540	Vectors for gene therapy of skin diseases. 2010 , 8, 582-91	1
539	Vektoren für die Gentherapie von Hautkrankheiten. 2010 , 8, 582-591	2
538	Molecular MR imaging of cancer gene therapy: ferritin transgene reporter takes the stage. 2010 , 9, 37-47	21
537	Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. 2010 , 16, 5852-61	93
536	Focus on adoptive T cell transfer trials in melanoma. 2010 , 2010, 260267	27
535	Strategies for targeting tumors and tumor vasculature for cancer therapy. 2010 , 69, 135-52	9
534	Lentiviruses: Vectors for Cancer Gene Therapy. 2010 , 155-179	
533	Gene therapy for bone healing. 2010 , 12, e18	57
532	STIMULI-SENSITIVE PARTICLES FOR DRUG DELIVERY. 2010 , 171-190	18
531	Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. 2010 , 2, 399-418	30
530	Tumour and dendrimers: a review on drug delivery aspects. 2008 , 60, 671-88	44
529	Personalized cancer vaccines. 2010 , 10, 1637-47	19

528	Adoptive cellular therapy. 2011 , 344, 149-72	18
527	Gene-Based Therapies for Cancer. 2010 ,	
526	Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells. 2011 , 22, 107-15	15
525	Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?. 2011 , 30, 238-93	4
524	Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. 2011 , 11, 855-73	111
523	Immunotherapy of melanoma: an update. 2011 , 20, 145-63	6
522	Viruses and Virus-Like Particles in Biotechnology. 2011 , 625-649	6
521	Therapeutic delivery using gene-delivery methods. 2011 , 2, 423-6	1
520	Viral Vectors for Gene Therapy. 2011 ,	8
519	Cancer Immunology and Immunotherapy. 2011 ,	1
518	White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. 2011 , 17, 1664-73	70
517	Introduction to gene therapy: a clinical aftermath. 2011 , 737, 27-44	10
516	Delivery of Nucleic Acids and Gene Delivery. 2011 , 411-444	6
515	Targeted gene therapy for the treatment of heart failure. 2011 , 27, 265-83	29
514	Gene delivery in salivary glands: from the bench to the clinic. 2011 , 1812, 1515-21	33
513	Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. 2011 , 11, 449-56	48
512	Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. 2011 , 2, 333-40	8
511	AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. 2011 , 52, 3051-9	29

510	Immunotherapy for melanoma. 2011 , 23, 163-9	30
509	The journal of cancer gene and cellular therapies. 2011 , 18, 1	1
508	Can genetic engineering of red blood cells and transfusion become close friends?. 2011 , 6, 17-20	
507	Hematopoietic stem cell expansion and gene therapy. 2011 , 13, 1164-71	20
506	Neural stem cell-based gene therapy for brain tumors. 2011 , 7, 130-40	47
505	[Clinical application of gene therapy. Previous experience and the future]. 2011 , 40, 254-62	1
504	The application of nanoparticles in gene therapy and magnetic resonance imaging. 2011 , 74, 577-91	28
503	An efficient parallel stochastic simulation method for analysis of nonviral gene delivery systems. 2011 ,	
502	Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability. 2011 , 25, 3219-28	3
501	Contributions of gene marking to cell and gene therapies. 2011 , 22, 659-68	18
500	Molecular and gene therapies for wound repair. 2011 , 395-415	
499	Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. 2012 , 2012, 616310	14
498	Viral and nonviral delivery systems for gene delivery. 2012 , 1, 27	484
497	T-cell therapy for cancer. 2012 , 4, 347-50	1
496	Coxsackievirus B3 used as a gene therapy vector to express functional FGF2. 2012 , 19, 1159-65	4
495	Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector. 2012 , 3, 835-56	25
494	Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. 2012 , 35, 276-82	28
493	[In vivo imaging of liposomal small interfering RNA (siRNA) trafficking by positron emission tomography]. 2012 , 132, 1373-81	2

492	Unexpected bilayer formation in Langmuir films of nucleolipids. 2012 , 28, 6816-25	11
491	IL-12 based gene therapy in veterinary medicine. 2012 , 10, 234	30
490	Stem Cells and Stress Injury: Role of Arginine Decarboxylase. 2012 , 195-202	
489	Current translational and clinical practices in hematopoietic cell and gene therapy. 2012 , 14, 775-90	8
488	Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. 2012 , 4, 520-31	2
487	Plasmid DNA production for therapeutic applications. 2012 , 824, 271-303	23
486	Cellular immunotherapy for cancer. Past, present, future. 2012 , 5, 81-84	1
485	Gene therapy for metabolic disorders: an overview with a focus on urea cycle disorders. 2012 , 35, 641-5	10
484	Genetic engineering of T cells for the immunotherapy of haematological malignancies. 2012 , 79, 4-14	6
483	Gene therapy for cardiovascular disease: perspectives and potential. 2013 , 58, 174-81	21
482	Chitosans for delivery of nucleic acids. 2013 , 65, 1234-70	150
481	CARs in chronic lymphocytic leukemia -- ready to drive. 2013 , 8, 60-70	16
480	Protein impurities from cell culture dramatically impact transduction efficiency of polymer/virus hybrid vectors. 2013 , 192, 1-11	2
479	RNAi-mediated MMP-9 silencing inhibits mouse melanoma cell invasion and migration in vitro and in vivo. 2013 , 37, 849-54	14
478	Gene Therapy: Vector Technology and Clinical Applications. 2013 , 399-412	
477	Advances in the development of cancer immunotherapies. 2013 , 34, 90-8	34
476	Gene therapy on the move. 2013 , 5, 1642-61	187
475	Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors. 2013 , 20, 807-15	24

474	New developments in lentiviral vector design, production and purification. 2013 , 13, 987-1011	67
473	Selection by RNA ^B RNA Interaction: Maximally Minimized Antibiotic Resistance-Free Plasmids. 2013 , 23-36	
472	History of gene therapy. 2013 , 525, 162-9	334
471	Cancer immunotherapies, their safety and toxicity. 2013 , 12, 631-45	94
470	Gene delivery platforms. 2013 , 18, 637-647	8
469	T lymphocytes are not immune. <i>Molecular Therapy</i> , 2013 , 21, 1114-5	11.7
468	What nurse practitioners should know about gene therapy. 2013 , 38, 16-22; quiz 22-3	1
467	Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. 2013 , 36, 276-86	2
466	"Model t" cells: a time-tested vehicle for gene therapy. 2013 , 4, 304	7
465	Gene and cell-mediated therapies for muscular dystrophy. 2013 , 47, 649-63	66
464	A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay. 2013 , 20, 169-76	6
463	Turning the Corner with Viral-based Gene TherapyDevelopment of the Rogue Biopharmaceutical. 2013 , 259-285	1
462	Permeabilization of adhered cells using an inert gas jet. 2013 ,	2
461	Gene Therapy. 2013 , 1	
460	Gene Therapy for Melanoma: Progress and Perspectives. 2013 ,	1
459	Clinical trials of immunogene therapy for spontaneous tumors in companion animals. 2014 , 2014, 718520	18
458	Bioethical conflicts of gene therapy: a brief critical review. 2014 , 60, 520-4	2
457	Nanopharmaceuticals (part 1): products on the market. 2014 , 9, 4357-73	378

456	How Primary Immunodeficiencies Have Made Gene Therapy a Reality. 2014 , 327-339	
455	Revisiting complexation between DNA and polyethylenimine: does the disulfide linkage play a critical role in promoting gene delivery?. 2014 , 14, 1807-15	9
454	The evolution of adenoviral vectors through genetic and chemical surface modifications. 2014 , 6, 832-55	45
453	Alpharetroviral vectors: from a cancer-causing agent to a useful tool for human gene therapy. 2014 , 6, 4811-38	17
452	Advanced Materials for Gene Delivery. 2014 , 995, 29-47	2
451	Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. 2014 , 2014, 161794	43
450	T-Cell Engineering and Expansion [GMP Issues]. 2014 , 131-177	1
449	Clinical Trial Design. 2014 , 179-201	
448	Gene therapy. 2014 , 20, 115-8	4
447	Progress and prospects for engineered T cell therapies. 2014 , 166, 818-29	13
446	Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. 2014 , 257, 127-44	109
445	Hematopoietic stem cells for cancer immunotherapy. 2014 , 257, 237-49	51
444	A Systems Biology Approach to Blood. 2014 ,	2
443	Retroviral vectors: from cancer viruses to therapeutic tools. 2014 , 25, 989-94	8
442	Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. 2014 , 16, 934-45	41
441	Gene Therapy for HIV. 2014 ,	1
440	Adoptive immunotherapy for cancer or viruses. 2014 , 32, 189-225	201
439	Molecular Biology of Cancer. 2014 , 1-22	

438	Gene therapy and DNA delivery systems. 2014 , 459, 70-83	311
437	Plasmid DNA production with Escherichia coli GALG20, a pgi-gene knockout strain: fermentation strategies and impact on downstream processing. 2014 , 186, 119-27	19
436	At the bedside: adoptive cell therapy for melanoma-clinical development. 2014 , 95, 875-82	14
435	Lignin nanotubes as vehicles for gene delivery into human cells. 2014 , 15, 327-38	89
434	Chimeric Antigen Receptors [CARs] 2014 , 519-560	
433	The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. 2014 , 2, 8	34
432	The FDA Review Process for Cancer Gene Therapy. 2014 , 503-515	
431	Current gene therapy trials for vascular diseases. 2014 , 14, 327-36	10
430	Salivary gland gene therapy: Personal reflections. 2014 , 56, 38-42	1
429	IL-2: the first effective immunotherapy for human cancer. 2014 , 192, 5451-8	660
428	Gene Therapy Used in Cancer Treatment. 2014 , 2, 149-162	45
427	Gene Therapy. 2014 ,	
426	Gene Therapy. 2014 , 399-422	
425	3: HISTORY OF GENE THERAPY. 2014 , 17-29	
424	Engineered T cell therapies. 2015 , 17, e19	5
423	Gene therapy: progress and predictions. 2015 , 282, 20143003	88
422	Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor. 2015 , 2, 15020	19
421	Selectable Markers for Gene Therapy. 2015 , 701-740	

420	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. 2015 , 9, 35-43	4
419	Single-Cell Characterization of in vitro Migration and Interaction Dynamics of T Cells Expanded with IL-2 and IL-7. 2015 , 6, 196	5
418	Lyophilized Biologics and Vaccines. 2015 ,	4
417	Cell-Based Gene Therapy. 2015 , 449-475	
416	Genetically engineered mesenchymal stromal cells producing TNF α have tumour suppressing effect on human melanoma xenograft. 2015 , 17, 54-67	30
415	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. 2015 , 67, 46-57	81
414	Gene and cell therapy for pancreatic cancer. 2015 , 15, 505-16	14
413	Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. 2015 , 22, 85-94	73
412	Current and future options of regeneration methods and reconstructive surgery of the facial skeleton. 2015 , 120, 315-23	15
411	Stabilization of Plasmid DNA and Lipid-Based Therapeutics as Dehydrated Formulations. 2015 , 211-254	
410	Adoptive cell transfer as personalized immunotherapy for human cancer. 2015 , 348, 62-8	1420
409	Bacteriophage-derived vectors for targeted cancer gene therapy. 2015 , 7, 268-84	28
408	Cellular therapy in tuberculosis. 2015 , 32, 32-8	21
407	Adeno-associated virus vector-based gene therapy for monogenetic metabolic diseases of the liver. 2015 , 60, 433-40	13
406	Genomics, Personalized Medicine and Oral Disease. 2015 ,	1
405	Advances in salivary gland gene therapy - oral and systemic implications. 2015 , 15, 1443-54	19
404	Integration of drug, protein, and gene delivery systems with regenerative medicine. 2015 , 5, 168-86	36
403	Gene Therapies for Cancer: Strategies, Challenges and Successes. 2015 , 230, 259-71	119

402	Applications of nanoparticle systems in gene delivery and gene therapy. 2016 , 44, 581-7	15
401	Strategies to Correct Nonsense Mutations. 2016 , 107-165	1
400	Polymeric nanoparticles for gene delivery. 2016 , 147-188	3
399	A nanogel with passive targeting function and adjustable polyplex surface properties for efficient anti-tumor gene therapy. <i>RSC Advances</i> , 2016 , 6, 84445-84456	3-7 8
398	Viral Gene Therapy for Central Nervous System Diseases. 2016 , 519-544	
397	Metastatic melanoma and immunotherapy. 2016 , 172, 105-110	31
396	Nanobiomaterials as gene-delivery vehicles. 2016 , 447-486	2
395	Therapeutic implications of melanoma heterogeneity. 2016 , 25, 497-500	24
394	Overview of Present Problems Facing Commercialization of Nanomedicines. 2016 , 3-36	3
393	Gene Therapy. 2016 , 1-19	
392	At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies. 2016 , 100, 1255-1264	6
391	Effects of molecular size and chemical factor on plasma gene transfection. 2016 , 55, 07LG06	3
390	Improvement of efficiency and viability in plasma gene transfection by plasma minimization and optimization electrode configuration. 2016 , 55, 07LG09	7
389	Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world. 2016 , 104, 42-72	5
388	Adoptive T-Cell Therapy for Cancer. 2016 , 130, 279-94	126
387	Novel Treatments in Development for Melanoma. 2016 , 167, 371-416	10
386	CAR-T Cell Therapy for Lymphoma. 2016 , 67, 165-83	89
385	Gene therapies development: slow progress and promising prospect. 2017 , 5, 1265293	68

384	Research on genodermatoses using novel genome-editing tools. 2017 , 15, 783-789	5
383	Synergistic effect of electrical and chemical factors on endocytosis in micro-discharge plasma gene transfection. 2017 , 26, 065016	13
382	Gene Therapy 2017: Progress and Future Directions. 2017 , 10, 242-248	89
381	Biotechnology and Computer Modeling on the Way to Treating Genetic Disorders. 2017 ,	0
380	Gene Therapy in the Nervous System: Failures and Successes. 2017 , 1007, 241-257	2
379	Challenges and opportunities in bioanalytical support for gene therapy medicinal product development. 2017 , 9, 1423-1430	7
378	Viral Vectors and Other Modulatory Biologics. 2017 , 171-205	1
377	Efficacy of vinyl imidazole grafted cationized pullulan and dextran as gene delivery vectors: A comparative study. 2017 , 105, 947-955	19
376	Functionalized 2D nanomaterials for gene delivery applications. 2017 , 347, 77-97	58
375	Forschung zu Genodermatosen durch neue Genom-Editing-Methoden. 2017 , 15, 783-790	0
374	Nanobiomaterials for Cancer Therapy. 2017 , 305-327	1
373	Personalized Medicine. 2017 , 101-133	
372	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. 2017 , 87, 101-112	38
371	Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy. 2017 , 7, 15996	11
370	Gene Therapy in the Treatment of Human Cancer. 2017 , 811-841	5
369	Expanded Umbilical Cord Cells: Benefits and Limitations. 639-648	
368	. 2017 ,	2
367	SiRNA Delivery with PEGylated Graphene Oxide Nanosheets for Combined Photothermal and Genetherapy for Pancreatic Cancer. 2017 , 7, 1133-1148	123

366	A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. 2017 , 8, 908	25
365	Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision. 2017 , 8, 1117	23
364	Viruses and Virus-Like Particles in Biotechnology: Fundamentals and Applications. 2017 , 633-656	6
363	Adoptive Cell Therapy for Cancer Using T-Cells Genetically Engineered to Express Chimeric Antigen Receptors. 591-601	
362	Precisely Defined Polymers for Efficient Gene Delivery. 2018 , 376, 2	4
361	Therapeutic Ultrasound for the Heart: State of the Art. 2018 , 39, 227-235	4
360	Shock wave-induced permeabilization of mammalian cells. 2018 , 26-27, 1-38	15
359	Gene therapy clinical trials worldwide to 2017: An update. 2018 , 20, e3015	433
358	Current strides in AAV-derived vectors and SIN channels further relieves the limitations of gene therapy. 2018 , 19, 69-75	
357	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. <i>Molecular Therapy</i> , 2018 , 26, 269-279	11.7 63
356	VIA-QMI: A visualized data analytic tool for Quantitative Multiplex Co-Immunoprecipitation(QMI) Platform. 2018 ,	
355	The intersection of affinity and specificity in the development and optimization of T cell receptor based therapeutics. 2018 , 84, 30-41	13
354	Carbon Nanomaterials for Photothermal Therapies. 2018 , 309-340	2
353	Criticality in tumor evolution and clinical outcome. 2018 , 115, E11101-E11110	13
352	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. 2018 , 9, 1300	337
351	Polybrene induces neural degeneration by bidirectional Ca influx-dependent mitochondrial and ER-mitochondrial dynamics. 2018 , 9, 966	5
350	Signification of protein p-53 isoforms and immune therapeutic success in chronic lymphocytic leukemia. 2018 , 106, 50-53	1
349	The rapidly evolving state of gene therapy. 2018 , 32, 1733-1740	18

348	Gene Therapy: Use of Viruses as Vectors. 2018 ,	2
347	New Tools for Epilepsy Therapy. 2018 , 12, 147	5
346	Bioprocesses for Cell Therapies. 2018 , 899-930	3
345	Genetic Engineering. 2018 , 507-532	
344	Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System. 2018 , 6,	26
343	Multifunctional Nanotherapeutics for Photothermal Combination Therapy of Cancer. 2018 , 1, 1800049	10
342	Ligand-directed tumor targeting with hybrid viral phage nanoparticles. 2018 , 483-516	0
341	Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced. 2018 , 11, 547-565	21
340	Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. 2019 , 471, 807-815	25
339	Regulation of Cell Membrane Transport by Plasma. 2019 , 173-247	
338	Anti-Colorectal Cancer Effects of Probiotic-Derived p8 Protein. 2019 , 10,	15
337	Pharmaceutical applications of natural polysaccharides. 2019 , 15-57	11
336	Importance of collision frequency in the molecular size dependency of gene transfer efficiency in the surface discharge method. 2019 , 58, SEEG05	3
335	Cellular Therapy for Melanoma. 2019 , 1-33	
334	Gene Therapy for Methylmalonic Acidemia: Past, Present, and Future. 2019 , 30, 1236-1244	11
333	T-cell-receptor cross-recognition and strategies to select safe T-cell receptors for clinical translation.. 2019 , 2, 1-10	9
332	Evaluation of surface glycoproteins of classical swine fever virus as immunogens and reagents for serological diagnosis of infections in pigs: a recombinant Newcastle disease virus approach. 2019 , 164, 3007-3017	9
331	. 2019 ,	8

330	Recent Trends of the Bio-Inspired Nanoparticles in Cancer Theranostics. 2019 , 10, 1264	87
329	Molecular therapeutics in hematology: gene therapy. 2019 , 319-338	
328	Gene Editing in Human Pluripotent Stem Cells: Recent Advances for Clinical Therapies. 2020 , 1237, 17-28	1
327	Introductory Chapter: Preface to Plasmids. 2019 ,	
326	GENE THERAPY. 2019 , 531-551	
325	Innovative approaches for cancer treatment: current perspectives and new challenges. 2019 , 13, 961	180
324	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV. 2019 , 10, 2310	15
323	Recent Progress of Polymeric Nanogels for Gene Delivery. 2019 , 39, 11-23	36
322	Engineering and Design of Chimeric Antigen Receptors. 2019 , 12, 145-156	149
321	Viral Vectors for Gene Therapy. 2019 ,	2
320	A Scalable Lentiviral Vector Production and Purification Method Using Mustang Q Chromatography and Tangential Flow Filtration. 2019 , 1937, 135-153	8
319	Gene Therapy: Current Applications and Future Possibilities. 2019 , 66, 37-54	10
318	Gene Therapy on the Road. 2019 , 19, 6	10
317	Nanocarrier-Based Gene Therapy Imaging Strategies. 2019 , 409-420	
316	The Application of Micro- and Nanomotors in Classified Drug Delivery. 2019 , 14, 2336-2347	23
315	The vicissitudes of gene therapy. 2019 , 8, 469-471	14
314	. 2019 ,	7
313	Editorial: Cellular Therapies in Cancer. 2019 , 10, 2788	3

312	Virus-like nanoparticles as a novel delivery tool in gene therapy. 2019 , 157, 38-47	59
311	The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. 2019 , 37, 2041-2049	8
310	Cancer Diagnostics and Therapeutics. 2019 , 33-66	
309	Interactions in DNA Condensation: An Important Factor for Improving the Efficacy of Gene Transfection. 2019 , 30, 284-292	20
308	Pharmaceutical applications of chitosan. 2019 , 263, 131-194	229
307	Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review. 2020 , 30, 313-335	6
306	Gene Replacement Therapy: A Primer for the Health-system Pharmacist. 2020 , 33, 846-855	8
305	Current Immunotherapeutic Strategies in Cancer. 2020 ,	4
304	Chimeric Antigen Receptor T Cells. 2020 ,	2
303	Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics. 2020 , 6, 167-181	7
302	Progress and setbacks: The two faces of technology emergence. 2020 , 49, 103874	7
301	Future directions for screening and treatment in congenital hearing loss. 2020 , 3, 175-186	9
300	Successful gene therapy requires targeting the vast majority of cancer cells. 2020 , 21, 946-953	1
299	Clinical Development of Gene Therapies: The First Three Decades and Counting. 2020 , 19, 387-397	16
298	CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. 2020 , 10, 1387	60
297	Advances in gene therapy for hematologic disease and considerations for transfusion medicine. 2020 , 57, 83-91	2
296	Commercial aspects and market potential of novel delivery systems for bioactives and biological agents. 2020 , 595-620	3
295	Globale Pharmaindustrie - quo vadis?. 2020 ,	1

294	Development of Theranostic Cationic Liposomes Designed for Image-Guided Delivery of Nucleic Acid. 2020 , 12,	5
293	Gene Editing and Genotoxicity: Targeting the Off-Targets. 2020 , 2, 613252	7
292	First person profile: Steven Rosenberg, MD, PhD: A trailblazer who helped launch the immunotherapy and gene therapy fields, Dr. Rosenberg continues to work toward curing common metastatic cancers. 2020 , 126, 4627-4629	
291	Gene Therapy for the Heart Lessons Learned and Future Perspectives. 2020 , 126, 1394-1414	34
290	Cell therapy. 2020 , 115-130	
289	Identification of the differential expression of genes and upstream microRNAs in small cell lung cancer compared with normal lung based on bioinformatics analysis. 2020 , 99, e19086	9
288	Biotechnology Business - Concept to Delivery. 2020 ,	0
287	Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer. 2020 , 7, 1903164	12
286	PEGylated Amine-Functionalized Poly(ϵ -caprolactone) for the Delivery of Plasmid DNA. 2020 , 13,	4
285	T Cell Engineering and the Rise of CAR-T Cell Therapies. 2020 , 69-90	
284	Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?. 2020 , 189, 408-423	16
283	Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy. 2020 , 8,	16
282	Tumor Immunology and Tumor Evolution: Intertwined Histories. 2020 , 52, 55-81	179
281	The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. 2020 , 22, 57-69	39
280	Development and Deployment of Gene Therapies. 2020 , 15-39	1
279	Gene therapy for inherited arrhythmias. 2020 , 116, 1635-1650	10
278	Conventional T cell therapies pave the way for novel Treg therapeutics. 2021 , 359, 104234	2
277	Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. 2021 , 55, 390-405	7

276	Exosome-mediated delivery of gene vectors for gene therapy. 2021 , 13, 1387-1397	29
275	Curative gene therapies for rare diseases. 2021 , 12, 267-276	4
274	CRISPR/Cas gene therapy. 2021 , 236, 2459-2481	34
273	Clarification of electrical current importance in plasma gene transfection by equivalent circuit analysis. 2021 , 16, e0245654	0
272	Genetic Modification of Tumor-Infiltrating Lymphocytes Retroviral Transduction. 2020 , 11, 584148	1
271	Bioinspired Nanoparticles in Cancer Theranostics. 2021 , 67-80	
270	Genetic Disease and Therapy. 2021 , 16, 145-166	3
269	Current Development of the Applications of Polymers in Gene Delivery. 2021 , 271, 04043	
268	Translation of gene therapies. 2021 , 683-697	
267	Cellular therapy for the treatment of solid tumors. 2021 , 60, 103056	5
266	TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential. 2020 , 10, 593848	6
265	Recent trends in cancer therapy: A review on the current state of gene delivery. 2021 , 269, 119087	34
264	Prospects Of Non-Coding Elements In Genomic Dna Based Gene Therapy. 2021 ,	0
263	Artificial Engineering of Immune Cells for Improved Immunotherapy. 2021 , 1, 2000081	2
262	Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future. 2021 , 43, e103-e138	2
261	Recent Advances in the Development of Magnetic Nanoparticles for Biomedical Applications. 2021 , 21, 2705-2741	1
260	The current landscape of nucleic acid therapeutics. 2021 , 16, 630-643	104
259	Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy. 2021 , 11, 11889	2

258	Engineering Gene Therapy: Advances and Barriers. 2021 , 4, 2100040	2
257	Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. 2021 , 12, 690499	10
256	Immersion in the search for effective cancer immunotherapies. 2021 , 27, 63	2
255	Human gene therapy: A scientometric analysis. 2021 , 138, 111510	1
254	Non-viral transfection technologies for next-generation therapeutic T cell engineering. 2021 , 49, 107760	12
253	Objectives, benefits and challenges of bioreactor systems for the clinical-scale expansion of T lymphocyte cells. 2021 , 49, 107735	2
252	Albumin Nanostructures for Nucleic Acid Delivery in Cancer: Current Trend, Emerging Issues, and Possible Solutions. 2021 , 13,	6
251	Radiopharmaceuticals: On-Going Research for Better Diagnosis, Therapy, Environmental, and Pharmaceutical Applications.	0
250	Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. 2021 , 69, 471-486	4
249	Interleukin-33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophage-Mediated Shedding Mechanism. 2021 , 8, e2101029	6
248	Gene therapy for bone healing: lessons learned and new approaches. 2021 , 236, 1-16	6
247	Human gene therapy: A patent analysis. 2021 , 803, 145889	1
246	Personalized cancer immunotherapy. 2022 , 399-426	
245	Oncolytic viruses in immunotherapy. 2022 , 375-437	
244	The evolution and history of gene editing technologies. 2021 , 178, 1-62	2
243	Bioinspired nanoparticles-based drug delivery systems for cancer theranostics. 2021 , 189-228	1
242	Gene therapy. 2021 , 165-183	
241	Cancer vaccines: translational strategies. 2021 , 307-328	

240	Zn-Promoted gene transfection efficiency for non-viral vectors: a mechanism study. 2021 , 45, 13549-13557	3
239	Phase I/II Manufacture of Lentiviral Vectors Under GMP in an Academic Setting. 2020 , 2086, 27-60	2
238	CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy. 2020 , 2121, 213-239	7
237	Gene Therapy. 1994 , 357-366	1
236	Gene Therapy Biotechnology. 1994 , 353-364	1
235	Intraperitoneal immunotherapy of cancer: a review of options for treatment. 1996 , 82, 13-40	1
234	Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. 1996 , 82, 115-46	33
233	Biomedical Research and Changing Concepts of Disease and Aging: Implications for Long-Term Health Forecasts for Elderly Populations. 1993 , 319-365	13
232	Cellular adoptive immunotherapy after bone marrow transplantation. 1995 , 76, 337-69	15
231	Origin and General Nature of Retroviruses. 1992 , 1-18	20
230	Mechanisms of Retrovirus Replication. 1992 , 159-298	46
229	Parvoviral Vectors for Human Hematopoietic Gene Therapy. 1999 , 89-122	1
228	Gene Marking and the Biology of Hematopoietic Cell Transfer in Human Clinical Trials. 1999 , 243-268	5
227	Preparation for a phase I/II study using autologous gene modified T lymphocytes for treatment of metastatic renal cancer patients. 1998 , 451, 547-55	5
226	Gene Therapy for AIDS. 1991 , 301-308	3
225	Clinical Trials of Immunotherapy of Cancer Utilizing Cytotoxic Cells. 1993 , 407-435	1
224	Gene Transfer via Particle Bombardment: Applications of the Accell Gene Gun. 1994 , 193-209	6
223	Gene Therapy for Adenosine Deaminase Deficiency and Malignant Solid Tumors. 1994 , 263-280	3

222	Engineered cell-based therapies: a vanguard of design-driven medicine. 2014 , 844, 369-91	2
221	Viral Vectors for Cancer Gene Therapy. 2005 , 379-391	1
220	Cancer-Related Gene Therapy Clinical Trials. 2005 , 427-440	1
219	Production of retroviral vectors for clinical use. 2008 , 433, 17-32	8
218	Detection of replication competent retrovirus and lentivirus. 2009 , 506, 243-63	13
217	The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. 2009 , 542, 5-54	27
216	Targeting Cancer with Genetically Engineered TCR T Cells. 2020 , 214, 129-151	3
215	Biotechnology: Discoveries and Their Applications in Societal Welfare. 2020 , 3-44	2
214	Gene Therapy: The Path Toward Becoming a Realistic Cure for Sickle Cell Disease. 2018 , 303-328	1
213	Gene transfer into hematopoietic stem cells: prospects for human gene therapy. 1992 , 177, 217-35	12
212	Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones. 1994 , 189, 9-34	31
211	Gene therapy using adenovirus vectors. 1995 , 199 (Pt 3), 297-306	18
210	Clinical Applications of Gene Therapy. 2010 , 139-281	2
209	Cancer gene therapy. 2009 , 589-612	2
208	Retroviral Vectors in Human Gene Therapy. 1995 , 77-107	2
207	The Wilson and Jungner principles of screening and genetic testing. 1999 , 1-34	1
206	Chitosan-Based Systems for Gene Delivery. 2019 , 229-267	5
205	Growing TIL and LAK Cells in Hollow Fibre Bioreactors. 1994 , 237-258	2

204	Introduction. 1999 , 3-22	16
203	Reconstitution of Immunity by Adoptive Immunotherapy with T Cells. 1999 , 137-177	1
202	Respiratory tract gene transfer. Transplantation of genetically modified T-lymphocytes directly to the respiratory epithelial surface.. 1991 , 266, 18339-18344	9
201	Retroviral transduction of human peripheral blood lymphocytes with bcl-xL promotes in vitro lymphocyte survival in pro-apoptotic conditions.	3
200	Genome-wide integration site detection using Cas9 enriched amplification-free long-range sequencing. 2021 , 49, e16	4
199	Human gene therapy. 1991 , 301, 353-63	43
198	Genes and molecular medicine in the future of organ transplantation. 1999 , 4, 65	2
197	Combining Crowdsourcing and Deep Learning to Assess Public Opinion on CRISPR-Cas9.	2
196	Human Gene Therapy. 1992 , 256, 808-813	47
195	Human immunodeficiency virus vectors for inducible expression of foreign genes. 1992 , 66, 2731-9	108
194	Adeno-associated virus type 2-mediated transfer of ecotropic retrovirus receptor cDNA allows ecotropic retroviral transduction of established and primary human cells. 1997 , 71, 5663-7	21
193	Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene. 1997 , 71, 7020-9	9
192	Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. 1991 , 11, 3374-3378	63
191	Cancer chemotherapy: identifying novel anticancer drugs. 1994 , 308, 1288-90	9
190	Cancer vaccines: progress reveals new complexities. 2002 , 110, 289-294	62
189	Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector. 1991 , 88, 1043-7	84
188	Percutaneous arterial gene transfer in a rabbit model. Efficiency in normal and balloon-dilated atherosclerotic arteries. 1992 , 90, 936-44	115
187	In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. 1996 , 97, 515-21	44

186	IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. 2011 , 121, 4746-57	238
185	Herpesvirus saimiri-transformed macaque T cells are tolerated and do not cause lymphoma after autologous reinfusion. 2000 , 95, 3256-3261	17
184	Gene, Oligonucleotide, and Ribozyme Therapy in the Eye. 2003 , 609-661	1
183	Review Biologicals & Immunologicals: Gene therapy: review of recent patenting activity. 1995 , 5, 219-226	2
182	Vaccine Trials for the Clinician: Prospects for Tumor Antigens. 1997 , 2, 284-299	14
181	Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors. 1997 , 2, 300-310	4
180	Gene Transfer Technology in Therapy: Current Applications and Future Goals. 1998 , 3, 225-236	6
179	Immunotherapy of human cancers using gene modified T lymphocytes. 2009 , 9, 396-408	25
178	Contemporary Animal Models For Human Gene Therapy Applications. 2015 , 15, 531-40	9
177	Historic Overview of Genetic Engineering Technologies for Human Gene Therapy. 2020 , 60, 483-491	2
176	Assessing Public Opinion on CRISPR-Cas9: Combining Crowdsourcing and Deep Learning. 2020 , 22, e17830	9
175	Repetitive Noninvasive Monitoring of HSV1-tk-Expressing T Cells Intravenously Infused into Nonhuman Primates Using Positron Emission Tomography and Computed Tomography with ¹⁸ F-FEAU. <i>Molecular Imaging</i> , 2009 , 8, 7290.2009.00022	3.7 21
174	Chimeric Antigen Receptor T Cell Therapy in Hematology. 2015 , 32, 285-94	6
173	A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme. 2011 , 1, 10-6	2
172	Gene therapy, early promises, subsequent problems, and recent breakthroughs. 2013 , 3, 249-55	22
171	Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells. 2021 , 32, 1044-1058	5
170	Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. 2021 , 13,	5
169	Genetic Modulation of Effector Cells to Enhance GVL Effects. 2000 ,	

168 Gene Therapy. **2000**, 317-336

167 Andere Therapien. **2000**, 595-615

166 Aktueller Stand der Gentherapie. **2000**, 297-374

1

165 Gene Therapy for Hematopoietic Disorders. **2000**, 519-532

164 T-bodies as antiviral agents. **2001**, 260, 271-300

5

163 Transfusion Medicine and the Development of Gene Therapy. **2001**, 273-280

162 Molecular Medicine in Organ Transplantation: How and When?. **2001**, 317-334

161 Gene Therapy. **2001**, 1881-1900

160 Molecular Strategies Interfering with Tumor Progression of Melanoma and Improving Anti-Tumor Immunity. **2001**, 245-273

159 Therapie mit Genen: Erfahrungen und Zukunftsperspektiven 10 Jahre nach ihrer klinischen Einführung. **2001**, 267-331

158 Immunotherapy of Advanced Melanoma Directed at Specific Antigens. **2002**, 141-156

157 Genetik und Gentechnologie. **2002**, 759-788

156 Gene Therapy for Glioma. **2002**, 11, 515-520

155 Applications of Gene Transfer in the Adoptive Immunotherapy of Cancer. **2002**, 241-255

154 Targeting Gene Therapy to the Tumor Vasculature. **2002**, 453-473

153 Gene Therapy for Cancer. **2002**, 17-32

152 Somatic Gene Therapy, Paradigm Shift or Pandora's Box. **2002**, 1-16

151 Front Matter. **2002**, i-xviii

150 Are Vaccinations for Prostate Cancer Realistic?. **2003**, 545-554

149 Cancer gene therapy. **2003**, 583-613

1

148 Cancer biotherapy: 2003 disease-related activity. **2003**, 615-674

147 Gene Marking Studies of Hematopoietic Cells. **2003**, 831-841

146 Gene Therapy for the Treatment of Cancer. **2004**, 439-456

145 Gen- und AntiGentherapie. **2006**, 836-846

144 Polymers Used for the Delivery of Genes in Gene Therapy. **2006**,

143 Steps in a Translational Cancer Gene Therapy Trial. **2007**, 447-460

142 Gene Therapy. **2008**, 717-729

141 Gene Therapy and Oncolytic Viruses. **2008**, 679-690

140 Gentherapie. **2008**, 379-394

139 Adoptive T Cell Immunotherapy. **2008**, 161-176

138 Gene Marking Studies of Hematopoietic Cells. **2008**,

137 Biological therapy of melanoma. **2009**, 633-644

136 Database setup for preclinical studies of gene-modified hematopoiesis. **2009**, 506, 467-76

135 Fundamentals of Molecular Biology and Gene Therapy. **2010**, 11-24

134 Gene Therapy-Basic Principles and the Road from Bench to Bedside.

133 Genetically Engineered Antigen Specificity in T Cells for Adoptive Immunotherapy. **2011**, 251-278

- 132 Historical Perspective. 1-34
- 131 Tumor Immunology and Immunotherapy. **2012**, 720-741
- 130 Gene therapy. **2013**, 1054-1065
- 129 Cancer Immunotherapy: Vaccines. **2014**, 347-370
- 128 Multifunctional Nanoscale Delivery Systems for Nucleic Acids. **2014**, 475-512
- 127 History of Gene Therapy. **2014**, 9-15
- 126 Transfection of Human Keratinocytes In Vitro with the Particle Mediated Gene Transfer and the Liposome-Mediated Gene Transfer Method. **1988**, 267-278
- 125 Immune System and Blood Cells. **1992**, 103-120
- 124 Prospects for Biological and Gene Therapies. **1992**, 25-32 1
- 123 ?????????(3) ??????????1992, 54, 520-531 2
- 122 Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies. **1992**, 59, 105-20
- 121 Outlook. **1992**, 287-293
- 120 Cytokine Gene Therapy of Cancer. **1992**, 37-47
- 119 Transfusion Medicine: The Impact of Biotechnology, Growth Factors, and Bioengineering. **1992**, 153-158
- 118 New Experimental Approaches to the Adoptive Immunotherapy of Cancer: Cytokines, Gene Therapy, Oncogenes and Transgenic Mice. **1992**, 165-188 1
- 117 Interleukin-2 and lymphokine activated killer (LAK) cells. **1993**, 29-43
- 116 Concepts and strategies for human gene therapy. **1993**, 165-179
- 115 Cytokine Gene Transfer into Tumor Cells and its Application to Human Cancer. **1993**, 361-367

114 Tumor Vaccines [Perspectives and Practice. **1993**, 297-311

113 Gene Therapy for Immunodeficiency and Cancer. **1993**, 553-555

112 Prospects and Limitations of Adoptive Immunotherapy and Gene Therapy. **1993**, 239-244

111 Transgenic Mouse Models for the Study of the Skin. **1993**, 245-268

110 Future prospects for Interleukin-2 therapy. **1993**, 169-185

109 Milestone and events in the early development of human gene therapy. **1993**, 3, 1-32

108 Immuntherapie in der Urologie [Eine kritische Bestandsaufnahme. **1993**, 23-33

107 Metastasiertes malignes Melanmom: Neue Therapieformen. **1993**, 167-178

1

106 PRENATAL APPLICATION OF SOMATIC GENE THERAPY. **1993**, 20, 611-620

9

105 Clinical application of gene transfer in oncology: preliminary results of a French study. **1994**, 861-864

104 Gene Transfer Technology: Alternative Techniques and Applications. **1994**, 177-219

103 Zelltypspezifische retrovirale Vektoren. **1995**, 380-388

102 Gene transfer and cancer chemotherapy. **1995**, 5, 125-139

1

101 Möglichkeiten einer Immuno- und Zytokintherapie beim metastasierenden Melanom. **1995**, 57-64

100 Ansätze zur Gentherapie. **1995**, 69-86

99 AIDS and HIV infection. **1995**, 5, 195-236

1

98 Carcinoembryonic antigen (CEA) promoter directed tissue specific gene expression in CEA expressing tumour cells. **1995**, 357-365

97 Immune System and Blood Cells. **1996**, 111-127

- 96 Analysis of sdi-1 Gene Functions in Human Malignant Gliomas. **1996**, 435-440
- 95 Human gene therapy in gastrointestinal diseases: in vivo and in vitro approaches. **1996**, 142, 51-61
- 94 Immuntherapie. **1996**, 763-794
- 93 Gene Therapy. **1996**, 577-594
- 92 Gene Therapy. **1997**, 417-444
- 91 Neue Konzepte der systemischen Therapie. **1997**, 535-541
- 90 Placental and/or Umbilical Cord Blood: An Alternative Source of Hematopoietic Stem Cells for Transplantation. **1997**, 90, 4665-4678 6
- 89 Gene Therapy for Pancreatic Cancer. **1998**, 295-318
- 88 Cancer Biotherapy: 1998 Disease-Related Activity. **1998**, 463-492
- 87 Genetik und Gentechnologie. **1998**, 733-761
- 86 Gene therapy of cancer. **1998**, 107-150
- 85 Gene Therapy for Cancer. **1998**, 133-145
- 84 Gene Marking to Establish the Biology of Minimal Residual Disease and Relapse. **1998**, 669-678
- 83 HIV Vector Mediated Gene Transfer into CD4 Positive Cells. **1998**, 313-317
- 82 Retroviral Vectors From Laboratory Tools to Molecular Medicines. **1998**, 193-218
- 81 Clinical Approaches to Cancer Gene Therapy. **1998**, 447-462
- 80 Expression in Eukaryotic Cells: Gene Transfer Using Retroviral Vectors. **1999**, 337-351
- 79 The Prehistory and History of the Uses of Interleukin-2 in Cancer Therapy. **1999**, 33-68

78 Gene Marking of T Lymphocytes. **1999**, 189-199

77 Gene Marking in Bone Marrow and Peripheral Blood Stem Cell Transplantation. **1999**, 171-187

76 Immunotherapy and Chemotherapy for Metastatic Renal Cell Carcinoma. **1999**, 117-129

75 Experimentelle Therapie von Lebermetastasen. **1999**, 167-174

74 Progress in the Molecular Medicine of Cancer. 129-152

73 Gene Therapy for Severe Haemoglobin Disorders.

72 Immunology of Cutaneous Tumors and Immunotherapy for Melanoma. **2015**, 277-298

71 Gene Therapy for Xerostomia. **2015**, 333-343

70 Criticality in Tumor Evolution and Clinical Outcome.

69 PLASMIDS - VECTORS FOR GENE THERAPY. **2019**, 56, 214-225

1

68 Optimization of an ex vivo gene transfer to the hamstrings tendons muscle remnants: potential for genetic enhancement of bone healing. **2019**, 60, 201-211

67 Adenosine Deaminase Deficiency: From the Discovery of Its Molecular Pathogenesis to Targeted Therapy. 1-12

1

66 Biopharmaceutical molecules. **2020**, 31-68

65 Biomedical applications of polysaccharides. **2020**, 1-34

2

64 Transfection of Stem Cells and Gene Therapy. **2020**, 145-162

63 Trends and Frontiers of Research on Cancer Gene Therapy From 2016 to 2020: A Bibliometric Analysis. **2021**, 8, 740710

5

62 Viral Vectors for Studying Drug-Seeking Behavior. **2021**, 233-261

61 Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?. **2021**, 55, 232-241

1

60	Assessing Public Opinion on CRISPR-Cas9: Combining Crowdsourcing and Deep Learning (Preprint).		
59	Gene and Cell Therapy. 2020 , 1-22		
58	Cellular Therapy for Melanoma. 2020 , 1267-1299		
57	Schwerpunkte der Forschungspipelines. 2020 , 87-111		
56	Embolotherapy Applications in Gene Therapy. 2006 , 295-302		
55	Cancer vaccines: progress reveals new complexities. 2002 , 110, 289-94		25
54	Cancer Gene Therapy. 2005 , 1-8		
53	Gene Therapy and Genetic Vaccines. 2021 , 129-142		
52	Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells. 1994 , 39, 279-285		1
51	Gene therapy for diseases of the nervous system. 1994 , 161, 260-3		3
50	Gene therapy: here to stay. 1995 , 152, 1605-13		2
49	Recent advances in the treatment of malignant melanoma with gene therapy. 1997 , 3, 636-51		
48	The Gordon Wilson Lecture. In vivo gene therapy: a strategy to use human genes as therapeutics. 1995 , 106, 87-99		3
47	Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. 2009 , 3, 63-75		15
46	Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU. <i>Molecular Imaging</i> , 2009 , 8, 230-7	3.7	16
45	Current status of immunotherapy for the treatment of lung cancer. <i>Journal of Thoracic Disease</i> , 2010 , 2, 237-44	2.6	16
44	A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells. <i>American Journal of Blood Research</i> , 2012 , 2, 98-104	1.6	1
43	Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. <i>P and T</i> , 2017 , 42, 452-463	1.4	34

42	Gene Therapy: Applications, Insights, and Prospects. <i>Gene, Cell and Tissue</i> , 2021 , In Press,	0.6	
41	Emerging therapeutic targets for cerebral edema. <i>Expert Opinion on Therapeutic Targets</i> , 2021 ,	6.4	1
40	The History of Cellular Therapies. <i>Cancer Drug Discovery and Development</i> , 2022 , 3-11	0.3	
39	Gene therapy strategies for the treatment of cancer. A review. 2000 , 2, 117-128		2
38	Polymer-based non-viral vectors for gene therapy in the skin. <i>Polymer Chemistry</i> , 2022 , 13, 718-735	4.9	2
37	Tumor Infiltrating Lymphocytes (TIL): From Bench to Bedside. <i>Cancer Drug Discovery and Development</i> , 2022 , 223-248	0.3	0
36	Cancer gene therapies progress in pre and postgenomics era. 2022 , 237-246		
35	Recent advances in biomaterial-boosted adoptive cell therapy.. <i>Chemical Society Reviews</i> , 2022 ,	58.5	1
34	Prodrug-based drug delivery approaches in cancer combination therapy. 2022 , 239-271		
33	GENE THERAPY ACCESS: GLOBAL CHALLENGES, OPPORTUNITIES AND VIEWS FROM BRAZIL, SOUTH AFRICA, AND INDIA.. <i>Molecular Therapy</i> , 2022 ,	11.7	1
32	Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
31	RNA delivery for cancer gene therapy. 2022 , 375-424		
30	Challenges in development and authorisation of gene therapy products. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022 , 22, 6-22	0.8	0
29	Table_1.XLSX. 2020 ,		
28	Table_2.XLSX. 2020 ,		
27	Table_3.XLSX. 2020 ,		
26	Presentation_1.pptx. 2021 ,		
25	Presentation_2.pptx. 2021 ,		

24	A Decade of Progress in Gene Targeted Therapeutic Strategies in Duchenne Muscular Dystrophy: A Systematic Review.. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022 , 10, 833833	5.8	0
23	Gen- und AntiGenherapie in der Onkologie. <i>Springer Reference Medizin</i> , 2022 , 1-8		0
22	Schwerpunkte der Forschungspipelines. 2022 , 95-128		
21	Targeted Therapeutics for Rare Disorders. 2022 ,		
20	Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics. <i>RSC Advances</i> , 2022 , 12, 20432-20446	3.7	1
19	Genetic etiology and clinical challenges of phenylketonuria. <i>Human Genomics</i> , 2022 , 16,	6.8	0
18	AAV gene therapy vectors in the TMJ. <i>Clinical and Experimental Dental Research</i> ,	1.9	0
17	Hybrid Genomics. 2022 , 163-180		
16	New Modalities. 2022 , 309-326		
15	Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies. 2022 , 5, 517-535		0
14	Ethical Issues in Human Gene Therapy. 1991 , 2, 267-274		0
13	Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing. 2023 , 28, 28-39		0
12	Successful Adoptive Cellular Immunotherapy Is Dependent on Induction of a Host Immune Response Triggered by Cytokine (IFN- γ and Granulocyte/Macrophage Colony-Stimulating Factor) Producing Donor Tumor-Infiltrating Lymphocytes. 1998 , 160, 334-344		6
11	A Double Recombinant Adenovirus Expressing the Costimulatory Molecule B7-1 (Murine) and Human IL-2 Induces Complete Tumor Regression in a Murine Breast Adenocarcinoma Model. 1998 , 160, 2531-2538		16
10	Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity. 1999 , 163, 507-513		51
9	CAR NK Cells: The Future is Now. 2023 , 7,		0
8	Tumor-infiltrating lymphocyte (TIL) therapy. 2023 , 133-147		0
7	Introduction on challenges for autoimmune diseases. 2023 , 1-8		0

6	Introduction on Cancer Immunotherapy. 2023 , 1-27	0
5	The First Three Decades of Gene Therapy. 2023 , 85, 17-22	0
4	Possibilities of Immunotherapy and Gene Therapy for Malignant Melanoma. 1993 , 9, 273-278	0
3	Eyclodextrin based nano gene delivery using pharmaceutical applications to treat Wolfram syndrome. 2022 , 13, 449-462	1
2	Antitumor Therapy Targeting the Tumor Microenvironment. 2023 , 2023, 1-16	0
1	Exploring microRNAs in craniofacial regenerative medicine.	0